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Besides the financial burden upon society, families undergo a substantial emotional burden when 
presented with a loved one affected by schizohprenia. Elucidation of the pathophysiology 
underlying the core features of schizophrenia is necessary for the development of more effective 
treatment targets. Cognitive deficits are regarded as a core feature of schizophrenia and are 
thought to arise from alterations in γ-aminobutyric acid (GABA)-containing interneurons in the 
dorsolateral prefrontal cortex (DLPFC). Specifically, postmortem studies have demonstrated 
decreased levels of the mRNA encoding the 67 kDa isoform of glutamic acid decarboxylase 
(GAD67), an enzyme that synthesizes GABA, and this alteration seems to be specific to certain 
subsets of GABA neurons. For example, parvalbumin and somatostatin mRNAs, which are 
expressed in separate subsets of GABA neurons, were decreased, whereas calretinin mRNA, 
expressed in a third subset of GABA neurons, was unchanged in schizophrenia. The studies in 
this thesis examined the compartmental and cellular expression of and the potential causal 
mechanisms of reductions in SST mRNA expression; furthermore, the disease and cellular 
specificity of and post-synaptic consequences of reductions in SST mRNA expression were 
examined. We found that reductions in the levels of SST mRNA appear to be restricted to SST 
interneurons that do not contain NPY mRNA in the gray matter and are due to reductions in 
expression per neuron. These alterations appear to be a consequence of impaired neurotrophin 
signaling through the trkB receptor. Also, the profile of alterations in GABA-related mRNA 
expression is specific to schizophrenia. Finally, a post-synaptic receptor of SST, SST receptor 
subtype 2 (SSTR2), mRNA is reduced in schizophrenia. Since the SST protein is putatively 
inhibitory and SST-containing interneurons target the distal dendrites of pyramidal neurons, 
these data suggest reduced inhibition of pyramidal neurons and may represent a compensatory 
mechanism to increase excitatory drive. We conclude that reductions in SST and SSTR2 mRNA 
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represent a downstream consequence of a neuropathological entity in the DLPFC of individuals 
with schizophrenia and contribute to cognitive dysfunction in schizophrenia. 
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1.0  OVERVIEW 
1.1 SCHIZOPHRENIA OVERVIEW 
1.1.1 Schizophrenia: A Devastating Illness 
Approximately 1% of the world’s population is affected by schizophrenia (Lewis and 
Lieberman, 2000). Individuals that are affected by this illness usually come to clinical attention 
in late adolescence through early adulthood (American Psychiatric Association, 1994; Lewis and 
Lieberman, 2000) and then many of these individuals experience disability for the rest of their 
lives. Besides the tremendous related financial burden upon society in terms of direct medical 
costs and lost productivity estimated to be around $62.7 billion in the US in 2002 (Wu et al., 
2005), family and friends undergo a substantial emotional burden when presented with a 
situation in which a loved one is affected by this disorder (Moller-Leimkuhler, 2006).  
1.1.2 Etiology of Schizophrenia 
The specific etiology of schizophrenia remains largely unknown; however, in general, 
individuals with schizophrenia have increased incidence of putative susceptibility genes (Owen 
et al., 2004) and increased incidence of various environmental factors that occur from conception 
to adolescence (Lewis and Levitt, 2002) leading many to hypothesize that a combination of 
genetic and environmental risks contribute to the etiology of schizophrenia (Tsuang, 2000). 
 Family, twin, and adoption studies demonstrate that the risk for developing schizophrenia 
is directly associated to the degree of shared genetics (Lewis and Lieberman, 2000); however, 
among monozygotic twins, concordance for schizophrenia only reaches ~50% (Gottesman, 
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1991). Additionally, several putative susceptibility genes on various chromosomes have recently 
been identified (Pulver, 2000; Owen et al., 2004), but these genes confer only a small degree of 
risk for schizophrenia. These studies suggest that the genetic risk for schizophrenia is polygenic 
and not sufficient for the presentation of the illness. Consistent with this hypothesis, many 
studies have identified environmental insults that occur across development that are associated 
with increased risk for schizophrenia (Lewis and Lieberman, 2000; MacDonald et al., 2000). 
Therefore, it is likely that a complicated convergence of genetic risk and environmental insults 
during development are involved in the development of schizophrenia. 
1.1.3 Clinical Manifestation of Schizophrenia: Cognitive Dysfunction as a Core Feature 
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), a diagnosis 
of schizophrenia includes the persistent presentation of 2 or more positive symptoms (e.g. 
delusions, hallucinations, disorganized thought) or negative symptoms (e.g. avolition, flat affect, 
alogia); furthermore, these symptoms must be accompanied by social or occupational 
dysfunction and must be not be due to other disorders (American Psychiatric Association, 1994). 
Although the criterion for a diagnosis of schizophrenia as outlined by the DSM-IV was created 
in order to achieve a high degree of concordance of diagnoses between clinicians, it relies on a 
cluster of heterogeneous overt clinical symptoms and the elimination of other disorders unlike 
many other clinical disease models (McCormick and Flaum, 2005). This is likely necessary due 
to the unknown nature of the etiology of schizophrenia. The heterogeneity of clinical symptoms 
manifested in individuals with schizophrenia highlights the necessity of identifying features of 
the disease that are common and are associated with functional outcomes. 
Of the clinical features of schizophrenia, positive symptoms, such as psychosis, are the 
most striking and most well known, but are not necessary for clinical diagnosis (Lewis et al., 
2005). Instead, cognitive dysfunction is becoming regarded as the core feature of schizophrenia 
(Elvevag and Goldberg, 2000) and many lines of evidence support this hypothesis. First, 
cognitive dysfunction is likely the most prevalent clinical feature among individuals with 
schizophrenia (Keefe et al., 2005). Second, cognitive dysfunction is found throughout life 
including childhood and adolescence (Breier et al., 1991; Heaton et al., 1994; Saykin et al., 1994; 
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Davidson et al., 1999); furthermore, unaffected family members of individuals with 
schizophrenia also demonstrate milder forms of cognitive dysfunction (Sitskoorn et al., 2004) 
indicating that this dysfunction is found before clinical manifestation of positive symptoms, not a 
result of medical treatment or progressive clinical deterioration associated with illness chronicity, 
and is related to genetic liability. Third, the degree of cognitive deficits in individuals with 
schizophrenia seem to be the best predictor of long-term functional outcome (Green, 1996) 
suggesting that these cognitive deficits rather than psychosis have a greater negative impact on 
social function in affected individuals. Unfortunately, current medical treatments of 
schizophrenia, which have been mostly discovered by serendipity rather than design, are mainly 
used to treat the positive symptoms of the illness and have a rather limited impact on cognitive 
dysfunction (Hyman and Fenton, 2003). A more thorough understanding of the pathophysiology 
and, perhaps, the pathogenesis underlying the core features found in schizophrenia is necessary 
for the development of more effective treatment targets and integral in the movement from the 
“bench to bedside”. 
1.2 WORKING MEMORY IN SCHIZOPRHENIA: ROLE OF ALTERED 
INHIBITORY CIRCUITRY IN THE DORSOLATERAL PREFRONTAL CORTEX 
Of the cognitive deficits found in schizophrenia, reduced working memory performance has been 
consistently observed in subjects with schizophrenia (Weinberger et al., 1986; Perlstein et al., 
2001; Callicott et al., 2003). Working memory refers to the ability to store pieces of information 
for a short amount of time in order to guide future behaviors. Working memory tasks are 
putatively mediated by the cortical circuitry located in the dorsolateral prefrontal cortex 
(DLPFC) (Funahashi et al., 1989; Funahashi et al., 1993; Botvinick et al., 2001) and subjects 
with schizophrenia demonstrate altered DLPFC activity during working memory tasks as 
compared to control subjects (Weinberger et al., 1986; Perlstein et al., 2001; Callicott et al., 
2003) suggesting altered DLPFC circuitry in individuals with schizophrenia. Because working 
memory seems to be a core feature of schizophrenia, it is important to examine the underlying 
pathophysiology leading to alterations in the performance of working memory tasks. 
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1.2.1 DLPFC Inhibitory Circuitry Underlying Working Memory 
The DLPFC has been identified as a critical node in working memory by both functional 
imaging studies in humans and electrophysiological studies in awake behaving monkeys 
(Funahashi et al., 1989; Funahashi et al., 1993; Weinberger et al., 2001; Miller and Cohen, 
2001). Spatial working memory has been extensively examined in monkeys performing an 
oculomotor delayed response (ODR) task. Spatial tuning of DLPFC neuron populations as well 
as coordinated and sustained firing of subsets of pyramidal neurons in the DLPFC during the 
delay period located between the presentation of the cue and the initiation of the behavioral 
response seem to be key components of the cellular basis underlying working memory 
(Funahashi et al., 1993; Rao et al., 1999). 
Both excitatory and inhibitory neurons of the DLPFC have been demonstrated to have 
preferred receptive fields and fire preferentially for cues directing behavioral responses to that 
receptive field during the delay period of the ODR task; and, this spatial tuning is thought to be 
one of the neuronal substrates of working memory (Funahashi et al., 1990; Chafee and Goldman-
Rakic, 1998; Rao et al., 1999; Rao et al., 2000). The generation of this spatial tuning has been 
suggested to be due to similar afferent inputs to adjacent neurons located in a functional 
microcolumn of the cortex and also due to the isodirectional inhibition of neighboring 
microcolumns (Rao et al., 2000). Traditional functional columns refer to a regional clustering of 
cells found in a column of the cortex that respond to similar features of “spots” of ~500 µm in 
diameter; microcolumns are considered a smaller column within these functional columns of 
~50-60 µm in diameter (Rao et al., 1999). Furthermore, this local inhibition seems to be due to a 
GABAA receptor-mediated event since GABAA receptor blockade increases cross-directional 
activity leaving isodirectional activity intact, thus, reducing spatial selectivity of neurons during 
the delay period (Rao et al., 2000). These data suggest that disturbances in inhibitory 
neurotransmission could play a prominent role in the dysfunction of the DLPFC in subjects with 
schizophrenia and these disturbances are an integral part of the pathophysiology underlying 
working memory disturbances in affected individuals (Lewis et al., 2005). 
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1.2.2 Selective Alterations in the Inhibitory Circuitry of the DLPFC in Individuals with 
Schizophrenia 
Several lines of evidence suggest that altered expression of markers of GABA neurotransmission 
is a common feature in the DLPFC of schizophrenia (Torrey et al., 2005; Akbarian and Huang, 
2006). These disturbances are highlighted by a reduction in the expression of mRNA that 
encodes for the 67 kD isoform of glutamate decarboxylase (GAD67), an enzyme involved in the 
synthesis of GABA in the DLPFC of individuals with schizophrenia (Akbarian et al., 1995; 
Guidotti et al., 2000; Volk et al., 2000; Straub et al., 2007; Hashimoto et al., 2008b). In addition, 
reduced GABA synthesis may be selectively mediated by the reductions in GAD67, because 
mRNA and protein levels of GAD65, an enzyme for GABA synthesis during high synaptic 
demand (Battaglioli et al., 2003), were found to have little to no alterations in the DLPFC of 
subjects with schizophrenia (Guidotti et al., 2000; Hashimoto et al., 2008c). 
The reduction in GAD67 mRNA is thought to be restricted to a subset of GABA neurons 
because this decrease is due to a marked reduction in GAD67 mRNA expression in a minority 
(~25-35%) of GABA neurons in the face of conserved expression in the remaining neurons 
(Volk et al., 2000). Furthermore, it appears that the affected GABA neurons include, at least, a 
subpopulation of inhibitory neurons that comprise ~25% of GABA neurons that expresses the 
calcium-binding protein, parvalbumin (PV), whereas the ~50% of GABA neurons that express 
calretinin (CR) appear to be unaffected (Hashimoto et al., 2003). However, the reduction in PV 
mRNA expression was shown to be specific to layers 3 and 4 (Hashimoto et al., 2003), whereas 
the alterations the alterations in GAD67 mRNA are found in layers 2-5; these laminar differences 
suggest that another subpopulation of GABA neurons are affected in schizophrenia. 
1.2.3 Disease Specificity of the Profile of Altered GABA-related mRNA  
According to the DSM-IV, a diagnosis of bipolar I disorder includes the presentation of 1 or 
more manic or mixed episodes and must be not be due to other disorders(American Psychiatric 
Association, 1994). The etiology of bipolar disorder is unclear, but genetic studies have 
demonstrated that bipolar disorder and schizophrenia, but not major depressive disorder, share 
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many putative susceptibility genes (Potash, 2006; Potash et al., 2007). Susceptibility genes refer 
to gene variations found through either genetic linkage or associational studies that cosegregate 
(provide a statistically higher proportion of people with) a particular gene variation to the 
positive diagnosis of the illness across families or populations, respectively. These data suggest 
that bipolar disorder also has a complex polygenic etiology similar to schizophrenia. 
Furthermore, cognitive deficits have been extensively demonstrated in euthymic individuals with 
bipolar disorder and subjects with bipolar disorder have similar cognitive deficits as seen in 
subjects with schizophrenia as compared to control subjects (Albus et al., 1996; Zubieta et al., 
2001; Martinez-Aran et al., 2004; Bora et al., 2007; Thompson et al., 2007; Martinez-Aran et al., 
2008). These impairments have also been shown to occur in unaffected relatives of subjects with 
bipolar disorder. For example, unaffected twins (Gourovitch et al., 1999) and unaffected first 
degree relatives (Ferrier et al., 2004) of subjects with bipolar disorder demonstrated cognitive 
deficits compared to normal subjects. These studies suggest that the cognitive deficits in 
individuals with bipolar disorder are state independent and are reliant on a genetic component 
rather than a consequence of illness chronicity or treatment. Additionally, these cognitive deficits 
have been shown to be the best predictor of functional outcome (Green, 2006; Martinez-Aran et 
al., 2007). These lines of evidence are similar to studies suggesting that cognitive deficits are a 
core feature of schizophrenia. 
Studies have also demonstrated that bipolar disorder also share neuropathology with 
schizophrenia. For example, alterations in inhibitory circuitry in various brain regions have been 
demonstrated in individuals with bipolar disorder which are similar to those found in individuals 
with schizophrenia (Kato et al., 2007). These alterations include reductions in the density of 
GAD67-positive cells in the hippocampus and anterior cingulate (Heckers et al., 2002; Woo et al., 
2004; Torrey et al., 2005). Furthermore, PV expression is affected in the hippocampus of 
individuals with bipolar disorder (Knable et al., 2004; Torrey et al., 2005) suggesting that this 
subset of GABA neurons are also affected in bipolar disorder. Furthermore, it has been 
demonstrated that GAD67 protein and mRNA expression is reduced in subjects with 
schizophrenia or bipolar disorder and a history of psychosis as compared to subjects with major 
depressive disorder or control subjects (Guidotti et al., 2000) suggesting that the GABA-related 
alterations are found in subjects with similar genetic susceptibility and are not due to common 
environmental factors that are associated with a chronic debilitating psychiatric illness (e.g. 
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social isolation and/or hospilization) often shared with individuals with major depressive 
disorder. 
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1.3 SOMATOSTATIN-CONTAINING INTERNEURONS 
The preceding chapter (1.2.2) outlined severe alterations in the inhibitory circuitry in the DLPFC 
of individuals with schizophrenia; and, that these alterations seem to be selective for certain 
subsets of GABA neurons. The specificity of such alterations and the mechanisms underlying 
these alterations are critical in understanding the pathophysiology of and, perhaps, the 
pathogenetic mechanisms underlying the disease. For example, chandelier neurons in the primate 
PFC express PV (Williams et al., 1992; Lund and Lewis, 1993) and chandelier neurons allow 
powerful modulation to the temporal coordination of aggregates of pyramidal neurons (Cobb et 
al., 1995) because these interneurons furnish inhibitory synapses on pyramidal neurons at the 
axon initial segment (AIS) (Williams et al., 1992). By staining the innervation of chandelier 
neurons onto AISs utilyzing a presynaptic marker (i.e. GABA membrane-1 transporter), 
characteristic vertical arrays of axon terminals, termed "cartridges", can be visualized and 
subsequently quantified. The density of these cartridges have been shown to be significantly 
reduced in the DLPFC of subjects with schizophrenia (Pierri et al., 1999) suggesting that 
inhibitory modulation of pyramidal neuron AISs is severely affected and, thus, temporal 
coordination of aggregates of pyramidal neurons may also be affected. Examining the subset of 
PV-containing interneurons allowed the ability to characterize a selective alteration in the 
inhibitory circuitry in the DLPFC of subjects with schizophrenia which can further drive 
hypotheses concerning the pathophysiology underlying phenotypic characteristics of individuals 
with schizophrenia [i.e. reductions in working memory performance (Lewis et al., 2005)]. This 
chapter will examine a subset of inhibitory interneurons that contain the neuropeptide, 
somatostatin (SST), which is expressed in a subpopulation of GABA neurons that do not contain 
either PV or CR (Kubota et al., 1994; González-Albo et al., 2001; Gonchar and Burkhalter, 2003; 
Sugino et al., 2006) and have been implicated in schizophrenia. 
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1.3.1 Alterations in SST-containing Interneurons in the DLPFC of Subjects with 
Schizophrenia 
As outlined in 1.2.2, the reduction in PV mRNA expression was shown to be specific to layers 3 
and 4 (Hashimoto et al., 2003), whereas the alterations the alterations in GAD67 mRNA are 
found in layers 2-5; these laminar differences suggest that another subpopulation of GABA 
neurons are affected in schizophrenia. Within the gray matter of the adult primate PFC, the 
greatest densities of SST-containing neurons are found in layers 2-superficial 3 and layer 5 
(Lewis et al., 1986; Hayes et al., 1991; Da Cunha et al., 1995) demonstrating that this 
subpopulation of GABA neurons are located within the layers of the cortex that did not 
demonstrate reductions in PV mRNA expression. 
In a recent study utilizing a custom-designed microarray of GABA-related transcripts, the 
most robust expression difference in the DLPFC of subjects with schizophrenia was a reduction 
in the levels of SST mRNA (Hashimoto et al., 2008a). The reduction in SST mRNA expression 
in schizophrenia was confirmed by both real-time qPCR and in situ hybridization in the same 
subjects (Hashimoto et al., 2008a). These data suggest that there are robust alterations in the SST 
interneurons within the DLPFC of subjects with schizophrenia. 
1.3.2 Properties of Somatostatin-containing interneurons 
GABA neurons have been classified by many different schemes based on characteristic 
properties including electrophysiology, dendritic arborization, axonal targets, and expression of 
various calcium-binding proteins and neuropeptides; however, these classification schemes do 
not reveal any straight-forward correlations with each other; and, thus, it has been difficult to 
reliably define particular subsets of GABA neurons.  
In general, SST interneurons seem to share some characteristics. In the neocortex of rats 
and primates, SST is exclusively localized to inhibitory GABA interneurons (Kubota et al., 1994; 
Kubota and Kawaguchi, 1994; Kawaguchi and Kubota, 1996; Gonzalez-Albo et al., 2001) and is 
expressed in a subpopulation of GABA neurons that do not contain either parvalbumin or 
calretinin (Kubota et al., 1994; Gonchar and Burkhalter, 1997; Gonzalez-Albo et al., 2001; 
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Sugino et al., 2006). Furthermore, in the rodent and monkey neocortex, SST interneurons tend to 
innervate the dendritic shafts of distal dendrites from pyramidal neurons (Hendry et al., 1984; 
DeLima and Morrison, 1989; Kawaguchi and Kubota, 1996; Melchitzky and Lewis, 2008) 
suggesting they may play a role in modulating inputs to pyramidal neurons.  
Other than these common characteristics, previous studies have demonstrated a large 
diversity of SST interneurons with respect to colocalization with other neuropeptides and 
calcium-binding proteins, morphological properties, and electrophysiological properties. In rat 
and monkey frontal cortex, NPY is present in ~30-40% of SST neurons (Hendry et al., 1984; 
Kubota et al., 1994); and, in the rat neocortex calbindin, a calcium-binding protein, is present in 
~50-85% of SST neurons dependent on cortical layer with increasing percentages in the deeper 
layers (Kawaguchi and Kubota, 1997; Gonchar and Burkhalter, 1997). In the rat neocortex, SST 
has also been suggested to be localized to a diverse group of morphologically distinct 
interneurons including basket cells (Wang et al., 2002), double-bouquet cells (Cauli et al., 2000), 
bitufted cells (Reyes et al., 1998), and the most commonly studied layer 1-targeting Martinotti 
cells (Kawaguchi and Kubota, 1996; Kawaguchi and Kubota, 1997; Kawaguchi and Kubota, 
1998; Kawaguchi and Kondo, 2002; Wang et al., 2004b; Ma et al., 2006). A common way in 
which subclasses of interneurons are electrophysiologically classified is by their firing patterns 
produced in response to step-current injections to the cell soma. Such studies have revealed that 
SST interneurons can exhibit low-threshold spikes (LTS) in at least some Martinotti cells 
(Kawaguchi and Kubota, 1996; Kawaguchi and Kubota, 1997; Reyes et al., 1998; Gibson et al., 
1999; Ma et al., 2006) although other studies have demonstrated quite a large diversity in the 
electrophysiological properties of SST interneurons (Wang et al., 2004b). In addition, subsets of 
SST neurons with different membrane properties and morphological features tend to differ in 
their laminar locations (Kawaguchi and Kubota, 1996; Ma et al., 2006). 
1.3.3 Neuropeptide Y-containing Subset of Somatostatin Neurons 
In rat and monkey frontal cortex, ~40% of SST neurons also express neuropeptide Y (NPY) and 
most NPY neurons contain SST (Hendry et al., 1984; Kubota et al., 1994). Both SST (Morris et 
al., 2008) and NPY (Caberlotto et al., 2000) mRNAs are expressed by neurons in the gray and 
white matter of the human DLPFC. Furthermore, most NPY mRNA expression in the human 
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cortex is located in deep layer 6 and the superficial white matter (Caberlotto et al., 2000). 
Consistent with these observations, the co-localization of SST and NPY mRNAs in the rodent 
cerebral cortex is most prominent in layer 6 and is uncommon in the superficial layers (Wang et 
al., 2004b). 
In a recent study utilizing both the gray and white matter from the DLPFC of subjects 
with schizophrenia or schizoaffective disorder, an expression difference was found in the levels 
of neuropeptide Y (NPY) mRNA (Hashimoto et al., 2008a) suggesting that the NPY-containing 
subclass of SST neurons is affected in these illnesses.  
 
1.3.4 Somatostatin Receptors 
As mentioned in the previous section (1.3.2), in the rodent and monkey neocortex, SST 
interneurons tend to innervate the dendritic shafts of distal dendrites from pyramidal neurons 
(Hendry et al., 1984; DeLima and Morrison, 1989; Kawaguchi and Kubota, 1996; Melchitzky 
and Lewis, 2008) suggesting they may play a role in modulating inputs to pyramidal neurons. 
There is a robust reduction in SST mRNA expression in the DLPFC of subjects with 
schizophrenia that is significantly correlated to reductions in GAD67 mRNA expression (Morris 
et al., 2008; Hashimoto et al., 2008a) suggesting that both somatostatin and GABA signaling are 
altered in this interneuron subtype and examining the postsynaptic targets of SST-containing 
interneurons could elucidate the functional implications of altered SST and GABA in these 
interneurons.  
There are six known G-protein coupled somatostatin receptor (SSTR) subtypes (SSTR1-
5) with SSTR2 having two isoforms (SSTR2a and SSTR2b) (Moller et al., 2003). The SSTRs 
have a putative inhibitory effect on neuronal excitability (Vezzani and Hoyer, 1999; Baraban and 
Tallent, 2004). Application of SST causes hyperpolarization of rodent hippocampal pyramidal 
neurons in vitro (Pittman and Siggins, 1981) by augmenting M-currents (Moore et al., 1988) and 
voltage-insensitive K
+
 leak current (Schweitzer et al., 1998).  
Mice with selective knockouts of the receptor subtypes demonstrate that the most 
abundant of these receptors are SSTR1 and SSTR2 (Videau et al., 2003) suggesting that these 
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receptor subtypes are the major receptors for the modulation of excitatory drive to pyramidal 
neurons by SST. Consistent with this hypothesis both SSTR1 and SSTR2 immuno-labeled cells 
have a putative pyramidal morphology and have labeled ascending processes in the rat isocortex 
(Schindler et al., 1997; Hervieu and Emson, 1998) suggesting a postsynaptic localization of these 
subtypes in pyramidal neurons. 
1.3.5 BDNF/TrkB signaling and SST mRNA expression 
BDNF (Weickert et al., 2003; Hashimoto et al., 2005) and TrkB, the principal receptor of BDNF, 
mRNA expression (Hashimoto et al., 2005; Weickert et al., 2005) are reduced in the DLPFC of 
subjects with schizophrenia. This reduction in BDNF and trkB mRNA expression could have 
implications for the pathophysiology underlying alterations in the inhibitory circuitry in the 
DLPFC of individuals with schizophrenia since BDNF/trkB signaling seems to regulate the 
development of GABA interneurons. In neuron cultures, BDNF/trkB signaling induces the 
expression of GABA-related proteins, including GAD67 (Mizuno et al., 1994; Bolton et al., 2000; 
Marty et al., 2000; Yamada et al., 2002) and is instrumental for the functional and morphological 
development and can help induce neurochemical differentiation of GABA neurons (Ventimiglia 
et al., 1995; Arenas et al., 1996; Vicario-Abejon et al., 1998; Rutherford et al., 1998; Bolton et 
al., 2000; Marty et al., 2000; Yamada et al., 2002; Kohara et al., 2003). Therefore, trkB 
activation mediated by BDNF may be important for the development of GABA interneurons 
including SST interneurons.  
The neurochemical expression of SST is thought to be mediated by BDNF/trkB 
signaling. Several lines of evidence support this hypothesis. First, approximately 50% of SST 
neurons express trkB (Gorba and Wahle, 1999). Furthermore, ~50% of SST neurons express 
trkB with predominant colocalization with trkB occurring in layers 2/3 and 5/6 (Gorba and 
Wahle, 1999) suggesting that many interneurons that contain SST also express trkB. Second, 
genetically manipulated mice that express reduced levels of BNDF demonstrated reductions in 
both SST protein and mRNA expression (Grosse et al., 2005; Glorioso et al., 2006). Third, 
previous studies have demonstrated that the addition of BDNF to cultured cortical cells or 
intraventricular administration of BDNF in rats increased SST mRNA and protein (Nawa et al., 
1994; Villuendas et al., 2001). Furthermore, the alterations in SST expression seem to be due to a 
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direct activation of trkB receptors rather than a consequence of other factors that may increase 
BDNF release such as neuronal activity. An increase in neuronal activity by application of 
bicuculline in rat hippocampal slices resulted in an increase of SST; however, this effect was 
abolished with an application of a tyrosine kinase receptor antagonist, K252a, suggesting that 
increased neuronal activity increased endogenous BDNF release and through a tyrosine kinase 
receptor mediated event subsequently increased SST expression. Therefore, these data are 
consistent with the hypothesis that BDNF/trkB signaling is an “upstream” event in the 
expression of SST. 
1.4 GOALS AND RELEVANCE OF THIS DISSERTATION 
In order to improve medical treatments of schizophrenia, it is necessary to understand the 
pathophysiology that underlies its core feature, cognitive deficits. Therefore, the experiments in 
this thesis are aimed at elucidating the alterations found in a subpopulation of SST-containing 
inhibitory interneurons in the DLPFC of subjects with schizophrenia. The results provide 
evidence for the critical functional roles of these interneurons in and possible pathogenetic 
mechanisms of altered working memory in schizophrenia.  The rationale and experiments of the 
following data chapters are briefly outlined:  
1.4.1 Somatostatin mRNA Expression in the DLPFC of Subjects with Schizophrenia  
In the DLPFC, SST mRNA expression is reduced in subjects with schizophrenia. However, the 
cellular substrate and causal mechanism of reduced SST mRNA expression in the DLPFC of 
subjects with schizophrenia had not been explored. Therefore, we utilized in situ hybridization 
and autoradiographic analyses in order to quantify SST mRNA: 
1) compartmental, laminar, and cellular levels in DLPFC of  subjects with schizophrenia 
2) expression in a mouse model in which trkB is reduced 
3) expression in a monkey model of chronic haloperidol treatment 
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1.4.2 Diagnostic Specificity of Alterations in GABA-related Transcript Expression  
The diagnostic specificity of the expression in SST mRNA and other prominent GABA-related 
transcripts had not been determined. Several lines of evidence suggest that individuals with 
bipolar disorder have similar genetic susceptibility and GABA-related alterations as individuals 
with schizophrenia. In contrast, subjects with major depressive disorder do not share these 
alterations. However, both of these psychiatric populations share common environmental factors 
that are associated with having a chronic debilitating psychiatric illness. Therefore, in order to 
determine the contribution of shared genetic susceptibility versus common environmental factors 
associated with a psychiatric disorder in mediating expression of GABA-related transcripts, we 
utilized real time qPCR to quantify the expression of SST, PV, CR, GAD67, and GAD65 mRNA 
expression in the DLPFC of subjects with bipolar disorder or major depressive disorder. 
  
1.4.3 NPY mRNA Expression in the DLPFC of Subjects with Schizophrenia 
In a custom-designed microarray of GABA-related transcripts, a robust expression difference in 
the DLPFC of subjects with schizophrenia was also found in the levels of neuropeptide Y (NPY) 
mRNA. NPY is present in ~30-40% of SST-containing interneurons suggesting that the NPY-
containing subclass of SST neurons is affected in schizophrenia. Therefore, we utilized in situ 
hybridization and autoradiographic analyses to quantify the compartmental levels of NPY 
mRNA expression in the DLPFC of subjects with schizophrenia 
 
1.4.4 Expression of SST receptor mRNAs in the DLPFC of Subjects with Schizophrenia 
The postsynaptic consequences of alterations in SST-containing interneurons are not known in 
schizophrenia. Somatostatin receptor subtypes 1 and 2 are the most abundant subtypes in the 
rodent. Therefore, we utilized in situ hybridization and autoradiographic analyses to quantify the 
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expression of SSTR1 and SSTR2 mRNAs in the DLPFC of subjects with schizophrenia and 
matched control subjects. Furthermore, we quantified SSTR2 mRNA expression in monkey 
models of chronic antipsychotic treatment. 
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2.0  ALTERATIONS IN SOMATOSTATIN MRNA EXPRESSION IN THE 
DORSOLATERAL PREFRONTAL CORTEX OF SUBJECTS WITH SCHIZOPHRENIA 
2.1 ABSTRACT 
Alterations in the inhibitory circuitry of the dorsolateral prefrontal cortex (DLPFC) appear to be 
a common feature of schizophrenia, and include reduced expression of the mRNA that encodes 
for somatostatin (SST), a neuropeptide present in a subpopulation of cortical GABA neurons. 
However, neither the cellular substrate nor the causal mechanisms for decreased SST mRNA 
levels in schizophrenia are known. Consequently, in this study we used in situ hybridization to 
quantify the compartmental, laminar, and cellular levels of SST mRNA expression in DLPFC 
area 9 of 23 matched pairs of schizophrenia and control subjects. In addition, we explored causal 
mechanisms that might contribute to decreased SST mRNA expression in schizophrenia by 
utilizing similar methods to analyze SST mRNA expression in several animal models. The 
expression levels of SST mRNA were significantly decreased in DLPFC layers 2 – superficial 6 
of subjects with schizophrenia; in contrast, SST mRNA expression in layers 1, deep 6 and the 
white matter did not differ between subject groups. At the cellular level, both the density of 
cortical SST mRNA-positive neurons and the expression of SST mRNA per neuron were 
reduced in the subjects with schizophrenia. These alterations appear to reflect the disease process 
of schizophrenia and are not the consequence of potential confounds, including chronic exposure 
to antipsychotic medications. Observations in both individuals with schizophrenia and 
genetically-engineered mice suggest that these changes are a down-stream consequence of 
impaired neurotrophin signaling through the trkB receptor. Together, these findings support the 
hypothesis that a marked reduction in SST mRNA expression in a subset of GABA neurons 
contributes to DLPFC dysfunction in schizophrenia.  
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2.2 INTRODUCTION 
Alterations in the inhibitory circuitry of the dorsolateral prefrontal cortex (DLPFC) appear to be 
a common feature of schizophrenia (Torrey et al., 2005; Akbarian and Huang, 2006). For 
example, reduced levels of the mRNA that encodes for the 67 kDa isoform of glutamic acid 
decarboxylase (GAD67), an enzyme for GABA synthesis, have been consistently found in the 
DLPFC of individuals with schizophrenia (Akbarian et al., 1995; Mirnics et al., 2000; Guidotti et 
al., 2000; Volk et al., 2000; Hashimoto et al., 2005; Straub et al., 2007). Furthermore, this 
decrease is due to a marked reduction in GAD67 mRNA expression in a minority (~25-35%) of 
GABA neurons, with apparently normal levels of expression in the remaining neurons (Volk et 
al., 2000). The affected neurons include the ~25% of GABA neurons that express the calcium-
binding protein parvalbumin (PV), whereas the ~50% of GABA neurons that express calretinin 
(CR) appear to be unaffected (Hashimoto et al., 2003). However, the deficits in PV expression 
are restricted to layers 3 and 4, whereas the alterations in GAD67 mRNA are found in layers 2-5; 
these laminar differences suggest that an additional subset of GABA neurons are affected in 
schizophrenia. 
In a recent study utilizing a custom-designed microarray of GABA-related transcripts, the 
most robust expression difference in the DLPFC of subjects with schizophrenia was a reduction 
in the levels of somatostatin (SST) mRNA (Hashimoto et al., 2008b), which is expressed in a 
subpopulation of GABA neurons that do not contain either PV or CR (Kubota et al., 1994; 
González-Albo et al., 2001; Gonchar and Burkhalter, 2003; Sugino et al., 2006). The reduction in 
SST mRNA expression in schizophrenia was confirmed by both real-time qPCR and in situ 
hybridization in the same subjects (Hashimoto et al., 2008a). However, neither the cellular 
substrate nor the causal mechanisms for decreased SST mRNA expression in schizophrenia have 
been explored.  
SST neurons are present in all layers of the cortex as well as in the underlying white 
matter. SST neurons in layer 1, deep layer 6, and the white matter are generated early in 
development and represent residual neurons from the embryonic preplate, whereas those 
generated later during the development of the cortical plate reside in layers 2 – superficial 6 
[(Kostovic and Rakic, 1980; Chun and Shatz, 1989b; Bayer and Altman, 1990); for review see 
(Allendoerfer and Shatz, 1994)]. Within the gray matter of the adult monkey and human DLPFC, 
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the greatest densities of SST neurons are found in layers 2-superficial 3 and layer 5 (Lewis et al., 
1986; Hayes et al., 1991; Da Cunha et al., 1995). In addition, subsets of SST neurons with 
different membrane properties and morphological features tend to differ in their laminar 
locations (Kawaguchi and Kubota, 1996; Ma et al., 2006). Thus, it is important to determine if 
the expression deficit in SST mRNA is 1) restricted to the gray matter compartment, 2) 
pronounced in certain cortical layers, and 3) confined to a subset of SST neurons. 
Consequently, in this study we used in situ hybridization and autoradiographic analyses 
to quantify the compartmental, laminar, and cellular levels of SST mRNA expression in DLPFC 
area 9 of 23 matched pairs of schizophrenia and control subjects. In addition, we explored 
potential causal mechanisms of decreased SST mRNA expression in schizophrenia by utilizing 
similar methods to analyze SST mRNA expression in several animal models.  
2.3 MATERIALS AND METHODS 
Human Subjects. With the consent of the surviving next-of-kin, brain tissue specimens were 
obtained from the Allegheny County Medical Examiner’s Office at the time of routine autopsy. 
Twenty-three subjects with schizophrenia (Table 1) were each matched with one control subject 
for sex, and as closely as possible for age, and postmortem interval (PMI). Subject groups did 
not differ in mean age, PMI, brain pH, RNA integrity number (RIN; as determined from the 
Agilent Bioanalyzer 2100) or tissue storage time at -80
0
 C (for all t(22) < 1.84; p > 0.08). 
An independent committee of experienced research clinicians made consensus DSMIV 
(Diagnosis and Statistical Manual of Mental Disorders, 1994) diagnoses based on medical 
records and structured interviews conducted with family members of the deceased. One control 
subject (987) had a history of post-traumatic stress disorder that had been in remission for 39 
years at the time of death. For the subjects with schizophrenia, the mean (SD) age of illness onset 
was 25.2 (8.0) years and the mean duration of illness was 23.3 (13.3) years. Fifteen subjects with 
schizophrenia had a history of substance (including alcohol) abuse and/or dependence disorder, 
although only 8 met criteria for dependence at time of death. Four subjects with schizophrenia 
(537, 622, 621, and 829) were free of antipsychotic medications at time of death for 9.6 months, 
19 
1.2 months, 8.2 years, and unknown length of time, respectively. Toxicology of all subjects 
detected positive plasma alcohol levels (0.01 and 0.06 %) in two control subjects (516 and 685) 
and one subject with schizophrenia (0.09 %; 656). All procedures were approved by the 
University of Pittsburgh’s Institutional Review Board for Biomedical Research and Committee 
for Oversight of Research Involving the Dead. 
 
Tissue Preparation. The right frontal cortex from each brain was blocked coronally, immediately 
frozen, and stored at -80°C. Serial sections with a thickness of 20 μm containing the superior 
frontal gyrus were cut, thaw-mounted onto glass slides and stored at -80°C until processed. The 
location of DLPFC area 9 was identified by cytoarchitectonic criteria in Nissl-stained sections as 
previously described (Glantz et al., 2000; Volk et al., 2000). Three sections per subject, at 
intervals of approximately 300 μm, were matched for anterior-posterior location within subject 
pairs, and used to assess SST mRNA expression.  
 
 In situ hybridization. Templates for the synthesis of the antisense and sense riboprobes for 
human and mouse SST mRNA were first generated by polymerase chain reaction (PCR). The 
specific primers amplified a 337 and 439 base pair (bp) fragment of human and mouse SST, 
respectively. These fragments corresponded to bases 112-448 of the human (GenBank 
NM_001048) and mouse (GenBank NM_009215) SST gene. Nucleotide sequencing confirmed 
100% homology of the amplified fragment to the previously reported sequence. The fragment 
was then subcloned into a plasmid (pSTBlue-1, Novagen, Madison, WI). The antisense and 
sense riboprobes were transcribed in the presence of 
35
S-CTP (Amersham Biosciences, 
Piscataway, NJ) using T7 and SP6 RNA polymerase, respectively. DNase I was used to digest 
the DNA template. The riboprobes were purified using RNeasy mini spin columns (Qiagen, 
Valencia, CA). One section from each pair was processed during a single run with the sections 
from each pair processed side by side. Prior to the hybridization reaction, tissue sections were 
fixed with 4% paraformaldehyde in PBS solution, acetylated with 0.25% acetic anhydrate in 0.1 
M triethanolamine/0.9% NaCl for 10 minutes, dehydrated with a graded alcohol series, and then 
defatted in chloroform for 10 minutes. The sections were then hybridized with 
35
S-labeled 
riboprobes (1.0 X 10
6
 cpm/μl) in hybridization buffer at 56°C for 16 hours. The hybridization
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a
PMI indicates postmortem interval in hours; 
b
storage time (months) at -80°C; 
c
ASCVD indicates arteriosclerotic cardiovascular disease; 
d
indicates prescribed antipsychotic 
medications at time of death;
 e
alcohol abuse, in remission at time of death; 
f
alcohol dependence, current at time of death; 
g
other substance abuse, current at time of death; 
h
alcohol 
abuse, current at time of death; 
i
other substance dependence, current at time of death; 
j
other substance abuse, in remission at time of death; 
k
alcohol dependence, in remission at 
time of death; 
l
other substance dependence, in remission at time of death; 
m
History of post-traumatic stress disorder, in remission 39 years at time of death
 
 Control Subjects  Schizophrenia Subjects 
Pair Case Sex/race Age PMI
a RIN Storage 
Timeb 
Cause of death
c Case DSM IV diagnosis Sex/race Age PMI
a RIN Storage 
timeb 
Cause of death
c Antipsychotic 
medicationd 
1 592 M/B 41 22.1 9.0 100 ASCVD 
 
533 Chronic undifferentiated 
schizophrenia 
M/W 40 29.1 8.4 110 Accidental 
asphyxiation 
Typical 
2 567 F/W 46 15.0 8.9 104 Mitral Valve prolapse 
 
537 Schizoaffective disorder F/W 37 14.5 8.6 109 Suicide by hanging None 
3 516 M/B 20 14.0 8.4 111 Homicide by gun shot 547 Schizoaffective disorder M/B 27 16.5 7.4 107 Heat Stroke Typical 
4 630 M/W 65 21.2 9.0 94 ASCVD 566 Chronic undifferentiated 
schizophreniae 
M/W 63 18.3 8.0 104 ASCVD Atypical 
5 604 M/W 39 19.3 8.6 97 Hypoplastic coronary 
artery 
581 Chronic paranoid 
schizophreniaf,g 
M/W 46 28.1 7.9 102 Accidental combined 
drug overdose 
Typical 
6 546 F/W 37 23.5 8.6 108 ASCVD 587 Chronic undifferentiated 
schizophreniae 
F/B 38 17.8 9.0 101 Myocardial 
hypertrophy 
Both 
7 551 M/W 61 16.4 8.3 107 Cardiac Tamponade 625 Chronic disorganized 
schizophreniah 
M/B 49 23.5 7.6 95 ASCVD Typical 
8 685 M/W 56 14.5 8.1 87 Hypoplastic coronary 
artery 
622 Chronic undifferentiated 
schizophrenia 
M/W 58 18.9 7.4 95 Right MCA 
infarction 
None 
9 681 M/W 51 11.6 8.9 87 Hypertrophic cardio-
myopathy 
640 Chronic paranoid 
schizophrenia 
M/W 49 5.2 8.4 93 Pulmonary embolism Atypical 
10 806 M/W 57 24.0 7.8 66 Pulmonary 
thromboembolism 
665 Chronic paranoid 
schizophreniaf 
M/B 59 28.1 9.2 90 Intestinal hemorrhage Typical 
11 822 M/B 28 25.3 8.5 63 ASCVD 787 Schizoaffective disorderi M/B 27 19.2 8.4 70 Suicide by gun shot Typical 
12 727 M/B 19 7.0 9.2 80 Trauma 829 Schizoaffective disorderf,j M/W 25 5.0 9.3 61 Suicide by drug 
overdose 
None 
13 871 M/W 28 16.5 8.5 53 Trauma 878 Disorganized schizophreniaf M/W 33 10.8 8.9 52 Myocardial fibrosis Atypical 
14 575 F/B 55 11.3 9.6 102 ASCVD 517 Chronic disorganized 
schizophreniaf 
F/W 48 3.7 9.3 111 Intracerebral 
hemorrhage 
Atypical 
15 700 M/W 42 26.1 8.7 84 ASCVD 539 Schizoaffective disorderk M/W 50 40.5 8.1 109 Suicide by combined 
drug overdose 
Atypical 
16 988 M/W 82 22.5 8.4 31 Trauma 621 Chronic undifferentiated 
schizophrenia 
M/W 83 16.0 8.7 95 Accidental 
asphyxiation 
None 
17 686 F/W 52 22.6 8.5 87 ASCVD 656 Schizoaffective disorderf F/B 47 20.1 9.2 91 Suicide by gun shot Atypical 
18 634 M/W 52 16.2 8.5 93 ASCVD 
 
722 Undifferentiated 
schizophreniaj,l 
M/B 45 9.1 9.2 81 Upper GI bleeding Typical 
19 852 M/W 54 8.0 9.1 56 Cardiac tamponade 781 Schizoaffective disorderk M/B 52 8.0 7.7 71 Peritonitis Typical 
20 987
m F/W 65 21.5 9.1 31 ASCVD 802 Schizoaffective disorderf,l F/W 63 29.0 9.2 67 Right ventricular 
dysplasia 
Both 
21 818 F/W 67 24.0 8.4 64 Anaphylactic reaction 917 Chronic undifferentiated 
schizophrenia 
F/W 71 23.8 7.0 44 ASCVD Typical 
22 857 M/W 48 16.6 8.9 55 ASCVD 930 Disorganized schizophreniaj,k M/W 47 15.3 8.2 41 ASCVD Typical 
23 739 M/W 40 15.8 8.4 79 ASCVD 933 Disorganized schizophrenia M/W 44 8.3 8.1 40 Myocarditis Atypical 
 Mean  48.0 18.0 8.7 80.0     47.9 17.8 8.4 84.3   
 SD  15.5 5.5 0.4 23.6     14.1 9.3 0.7 23.7   
                 
Table 1 Characteristics of Subjects 
21 
buffer contained 50% formamide, 0.75 M NaCl, 20 mM 1,4-piperazine diethane sulfonic acid, 
pH 6.8, 10 mM EDTA, 10% dextran sulfate, 5X Denhardt’s solution (0.2 mg/ml Ficoll, 0.2 
mg/ml polyvinylpyrrolidone, 0.2 mg/ml BSA), 50 mM dithiothreitol, 0.2% SDS, and 100 μg/ml 
yeast tRNA. Following the hybridization reaction, sections were washed in a solution of 0.3 M 
NaCl, 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, and 50% formamide at 63°C, treated with 
RNase A (20 μg/ml) at 37°C, washed in 0.1 X SSC (1.5 mM NaCl, 150 μM sodium citrate) at 
67°C, dehydrated through a graded ethanol series, and air dried. The sections, as well as carbon-
14 radioactive standards, were exposed on the same BioMax MR film (Kodak, Rochester, NY) 
for 3 days. Afterward, sections were coated with NTB2 emulsion (Kodak) diluted 2:1 with water. 
The consistency of the thickness of the emulsion was maintained with use of a mechanical dipper 
(Auto-dip Emulsion Coater, Ted Pella, Redding, CA) at a constant withdrawal speed (64 
mm/min) and temperature (43°C). The emulsion was exposed for 18 days at a constant 
temperature of 4°C. The slides were developed with D-19 (Kodak) and counterstained with 
Cresyl-violet. 
 
Quantification of mRNA expression levels. Each section was randomly coded, so that subject 
number and diagnosis were unknown to the single rater (HMM). Autoradiographic films were 
trans-illuminated and captured on video camera under controlled conditions, digitized, and 
analyzed with a Microcomputer Imaging Device (MCID; Imaging Research Inc., London, 
Ontario, Canada). Digitized images of adjacent sections stained with cresyl violet were 
superimposed onto autoradiographic images to draw contours of the full cortical thickness of the 
zones of area 9 that were cut perpendicular to the pial surface. Optical density measures within 
each sampled area were calibrated to radioactive carbon-14 standards (ARC Inc., St. Louis, MO), 
exposed on the same autoradiographic film, and expressed as nanocuries per gram (nCi/g) of 
tissue. The mean (SD) total area of gray matter sampled in each subject was 381 (141) mm
2
 for 
control subjects and 353 (101) mm
2
 for subjects with schizophrenia. Optical density measures in 
the superficial white matter were determined in a zone 800 μm below, and with a contour that 
followed, the layer VI/white matter border of the previously sampled gray matter zones. The 
mean total areas of sampled superficial white matter per subject were 32 (14) mm
2 
for control 
subjects and 30 (10) mm
2
 for subjects with schizophrenia. Total white matter was determined by 
outlining the gray matter/white matter border and including all white matter on the section. The 
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mean total areas of the sampled total white matter per subject were 280 (117) mm
2
 for control 
subjects and 277 (105) mm
2
 for subjects with schizophrenia.  
SST mRNA expression as a function of cortical layer was determined in a series of 
cortical traverses (1-2 mm in width) extending from the pial surface to the white matter. Three 
cortical traverses were sampled for each section (nine traverses per subject) (Figure 1A). Each 
traverse was divided into 50 equal bins parallel to the pial surface and the optical density was 
determined for each bin. These bins were then combined into zones that approximated laminar 
boundaries based on previous studies (Akbarian et al., 1995; Pierri et al., 1999). These zones 
(i.e., bins 1-5, 6-15, 16-25, 26-30, 31-40, and 41-50) corresponded to layers 1, 2/superficial 3 
(2/3s), deep 3 (3d), 4, 5, and 6, respectively (Figure 1B). The mean OD was calculated for each 
zone. Background measures were sampled from deep white matter where no specific expression 
of SST mRNA was observed. All sampled areas were corrected by subtracting the corresponding 
background measure from the same slide.  
Evaluation of mRNA expression at the cellular level was performed by determining silver 
grain accumulation on emulsion-dipped, Nissl counter-stained sections. Using the MCID system 
coupled to a microscope equipped with a motor-driven stage, two regions of interest (ROI) 
(Figure 1B’) were defined in 1-mm-wide cortical traverses (3/section; 9/subject). The superficial 
ROI extended from 10-30% of the distance from the pial surface to the white matter 
(corresponding to layer 2-superficial 3), and the deep ROI extended from 60-80% 
(corresponding to layer 5). Four sampling frames (120 X 170 μm) were placed in each ROI such 
that the edges of the frames were equidistant from the border of the ROI and the edge of the next 
sampling frame. Within each frame, a circle with a fixed diameter of 22 μm (380 μm2) was 
placed over each Nissl-stained nucleus under brightfield illumination using an unbiased inclusion 
and exclusion rule (Figure 1C), and then the number of grains within the circle were counted in 
the corresponding dark-field image (Figure 1C’). Because RNase A treatment during the in situ 
hybridization procedure degrades Nissl-stainable substances within the cytoplasm, it was not 
possible to draw contours around the soma of neurons. In a previous study, we determined that 
the largest cross-sectional area of human DLPFC GABA neurons is ~400 μm2 (Volk et al., 
2000). The use of fixed diameter sampling does not account for potential differences in somal 
size across subject groups. However, this confound is unlikely because the somal size of GAD67 
mRNA-positive neurons has been reported to be unchanged in subjects with schizophrenia
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Figure 1 Schematic representation of the sampling strategy for grain analysis of SST mRNA 
expression.  
A, Camera lucida drawing of the portion of DLPFC containing area 9, with the dotted line 
indicating the grey/white matter border. Three cortical traverses from the pial surface to white 
matter were placed in each section. B, Brightfield photomicrograph of a representative traverse 
from a Nissl-stained section. B’, Darkfield photomicrograph of an adjacent emulsion-dipped 
section illustrating silver grain accumulation over neuronal nuclei. Two ROIs (large dashed 
rectangles) were placed in layers 2/3s and 5. Four sampling frames (smaller dashed rectangles) 
were placed in each zone.   C, Representative brightfield image in which Nissl-stained neuronal 
nuclei were identified and sampled based upon unbiased inclusion and exclusion rules. Each 120 
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X 170 μm counting frame had broken and solid lines indicating inclusion and exclusion 
boundaries, respectively. Circles with a 22 μm diameter were centered over all neuronal nuclei 
(solid circles) and four glia nuclei (dashed circles) in every counting frame and the number of 
grains in each circle were counted in the corresponding darkfield image (C’). 
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 (Akbarian et al., 1995; Volk et al., 2000). Background grain density was measured in each 
sampling frame by using the same sampling circle to count grains over four glial nuclei in each 
sampling frame. The smaller size and intense cresyl violet staining of glial nuclei distinguished 
them from the larger, more faintly stained neuronal nuclei (Figure 1C). Total neuron numbers 
sampled in the superficial ROI were 13,791 and 14,593 for control and subjects with 
schizophrenia, respectively. Deep ROI total neuron numbers sampled were 13,981 and 14,356 
for control and subjects with schizophrenia, respectively. 
 Grain density per neuron (i.e., number of grains within the 22 μm diameter circle) was 
calculated for all neurons. Specifically-labeled neurons were determined by creating a threshold 
of grains per neuron. For both subject groups, histograms (natural log transformed) of the grain 
density of all sampled neurons had a bimodal distribution representing nonspecifically- and 
specifically-labeled neuron populations (Gerfen et al., 1991). A point of rarity between these 
populations was used to calculate the threshold above background needed to distinguish the 
labeled neuron population. Using this threshold, which was equal to 7X background grain 
density, histograms (natural log transformed) of the grain density of all sampled neurons 
appeared unimodal and normal in both subject groups. Therefore, grain densities of ≥ 7X 
background were considered to be specifically-labeled and are referred to as SST mRNA+ cells.  
Haloperidol Exposed Monkeys. To mimic the treatment of schizophrenia with high doses of 
haloperidol, four pairs of young adult, male macaque monkeys (Macaca fascicularis), matched 
for age and weight, were chronically exposed to haloperidol decanoate [mean (SD) trough 
plasma level, 4.3 (1.1) ng/ml] and benztropine mesylate (1 mg b.i.d.) to treat extrapyramidal 
symptoms for 9 – 12 months, as previously described (Pierri et al., 1999).  
 Processing of monkey brain tissue was conducted as previously described (Hashimoto et 
al., 2003). Briefly, coronal sections with a thickness of 16 μm were cut from fresh-frozen tissue 
blocks containing the middle one-third of the principal sulcus. Two serial sections from each 
animal were processed for SST mRNA expression utilizing the 
35
S-labeled riboprobe as 
described above. The optical density of the cortex was determined for the full cortical thickness 
of areas 9 and 46 cut perpendicular to the pial surface similar to the methods in the human study. 
Background measures were sampled from deep white matter where no specific expression of 
SST mRNA was observed. All sampled areas were corrected by subtracting corresponding 
background measures from the same section. 
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Genetically Engineered Mice. To test the effect of decreased expression of the neurotrophin 
receptor tyrosine kinase B (trkB) on the expression of SST mRNA, we used trkB hypomorphic 
mice (Xu et al., 2000) in which the first coding exon of the trkB gene is replaced with a trkB 
cDNA unit flanked by two loxP sites (fBZ locus). These mice were generated with 129 strain 
mice-derived embryonic stem cells and C57BL/6 mice-derived blastocytes (Xu et al., 2000) and 
back-crossed into C57BL/6 mice for at least five generations. Wild-type C57BL/6 mice (Jackson 
Laboratory, Bar Harbor, ME) were used as control. Homozygous (fBZ/fBZ) and heterozygous 
(fBZ/+) animals were reported to express ~25% and ~62%, respectively, of the trkB protein 
levels present in the wild-type animals (Xu et al., 2000; Rohrer, 2001; Rico et al., 2002).  
Animals with the fBZ/fBZ genotype do not express the truncated isoforms of trkB (Xu et al., 
2000). Heterozygous and homozygous mice for the fBZ locus and wild-type controls (n=3 for 
each group) were euthanized at 8 weeks of age. 
 The optical density from the autoradiographic film was measured for SST mRNA 
expression of the cortex in the PFC, including the cingulate and prelimbic cortices, as described 
for the human study. All density measures were corrected by subtracting background measures in 
the corpus callosum. 
 
Statistical Analyses. Analyses were performed on SPSS (SPSS Inc., Chicago, IL). Analysis of 
covariance (ANCOVA) models were used to test differences in SST mRNA expression between 
control subjects and subjects with schizophrenia. The data were averaged across the three 
sections for each subject before statistical analysis. The first ANCOVA model used diagnostic 
group as the main effect, pair as a blocking effect, and storage time and RIN as covariates. The 
pair effect reflects the matching of individual subject pairs for sex, age and PMI. RIN was 
included as a covariate because it reflects mRNA integrity (Stan et al., 2006). Subject pairing 
may be considered an attempt to balance the two diagnostic groups with regard to the 
experimental factors instead of a true statistical paired design. Thus, to validate the first model, a 
second ANCOVA model was performed with a main effect of diagnostic group and covariates of 
sex, age, PMI, RIN, and storage time. Storage time as a covariate was not significant in either 
model and, thus was excluded in the reported analyses. Both models produced comparable 
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results for diagnostic group effect; however, because the effect of age on SST mRNA expression 
was significant, the results of the second model are reported.  
 In order to correct for multiple comparisons in the laminar analyses, significance of the 
diagnostic group effect was determined for individual layers using the Holm simultaneous 
inference procedure (Holm, 1979) as previously described (Volk et al., 2002). To maintain 
consistency, the reported p-values for each laminar comparison have been adjusted to correspond 
to the family-wise error rate of 0.05. 
The potential influence of sex, diagnosis of schizoaffective disorder, history of substance 
abuse/dependency, use of antidepressant medication at time of death, use of 
benzodiazepines/valproate at time of death, or suicide on the within-pair percentage of 
differences in mRNA expression was assessed by two-sample t-test analyses. Correlations 
between age and mRNA expression were assessed by Pearson’s correlation analyses. 
 For the haloperidol-treated monkeys, paired t-test analyses were used to assess the effects 
of treatment group on SST mRNA expression. 
 For the trkB hypomorphic mice, the effects of genotype on SST mRNA expression were 
determined by a single-factor ANOVA. Tukey’s multiple comparison test was used in post-hoc 
comparisons across genotypes. 
 
2.4 RESULTS 
Specificity of SST riboprobe 
 
Several lines of evidence confirm the specificity of the riboprobe for SST mRNA used in this 
study. First, the distinctive laminar distribution of SST mRNA expression is very similar to that 
previously reported for both SST-immunoreactive cell bodies in monkey and human prefrontal 
cortex (Lewis et al., 1986; Hayes et al., 1991) and SST mRNA expression in monkey prefrontal 
cortex (Da Cunha et al., 1995). Specifically, the density of SST mRNA+ neurons was lowest in 
layer 1, highest in layers 2 and superficial 3, moderate in deep layer 3 and layer 4, high in layer 
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5, and moderate in layer 6 (Figure 1B’, Figure 2A). Second, the presence of intensely SST 
mRNA+ neurons in the superficial white matter (Figure 1B’, Figure 2A) is consistent with 
previous studies of SST-immunoreactive cell bodies in human and monkey prefrontal cortex 
(Lewis et al., 1986; Hayes et al., 1991) and SST mRNA expression in the monkey prefrontal 
cortex (Da Cunha et al., 1995). Third, sense riboprobes for SST mRNA showed an absence of 
signal above background (data not shown).  
 
Compartmental expression of SST in DLPFC area 9 of control subjects and individuals with 
schizophrenia 
We previously reported reduced SST mRNA expression by microarrary, qPCR, and in situ 
hybridization in the DLPFC of subjects with schizophrenia (Hashimoto et al., 2008a). However, 
whether this expression deficit was specific to the gray matter or also present in the white matter 
was not examined. Consistent with qualitative impressions (Figure 2), quantitative measures of 
SST mRNA expression in the gray matter of DLPFC area 9 confirmed that the mean (±SD) 
optical density of gray matter was significantly (F(1,40) = 18.07; p < 0.001) decreased by 36% in 
subjects with schizophrenia (55.8 ± 31.9 nCi/g) compared to control subjects (87.5 ± 22.9 nCi/g). 
Optical density measurements in the gray matter were lower in the subjects with schizophrenia 
for 19 of the 23 subject pairs (Figure 3A). In contrast, mean film OD from the total white matter 
did not significantly differ (F(1,40) = .72; p = .40) between control subjects (18.8 ± 5.6 nCi/g) and 
subjects with schizophrenia (17.0 ± 5.3 nCi/g) (Figure 3B). Because SST mRNA expression was 
most dense in the superficial white matter (Figure 2), the OD was also determined from contours 
in the 800 μm of white matter immediately below the layer 6-white matter border. These 
measures also did not differ (F(1,40) = 1.74; p = .20) between control subjects (33.8 ± 10.9 nCi/g) 
and subjects with schizophrenia (28.3 ± 10.1 nCi/g) (Figure 3C). 
 
Examination of factors that may affect cortical expression of SST mRNA 
In the second ANCOVA model, age was a significant (F(1,40) = 19.24; p < 0.0001) determinant of 
SST mRNA levels in the gray matter. Indeed, OD measures in the gray matter contours were 
negatively correlated with age in both control subjects (r = -0.74; p < 0.0001) and subjects with 
schizophrenia (r = -0.51; p = 0.01) (Figure 4). However, the within-subject pair percent 
differences in SST mRNA expression in the gray matter did not differ as a function of sex, 
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Figure 2 Representative film autoradiograms from one pair of subjects illustrating SST mRNA 
expression in human DLPFC.  
The densities of hybridization signals are represented in a pseudocolor manner according to the 
calibration bar (center). The solid and dashed lines indicate the pial surface and the gray/white 
matter border, respectively. Expression of SST mRNA in the cortical gray matter is reduced in 
the subject with schizophrenia (B) relative to the matched control subject (A). 
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Figure 3 SST mRNA expression levels assessed by autoradiographic film optical density (OD) 
measures in DLPFC area 9 of subjects with schizophrenia (gray circles) and control subjects 
(black circles).  
Subjects in each pair are connected by black lines and the mean expression levels for each 
subject group are represented by a horizontal line. The expression of SST mRNA is significantly 
reduced in the gray matter (A), but not in the total white matter (B) or the superficial white 
matter (C) of the schizophrenia subjects. 
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Figure 4 Optical density (OD) measures of SST mRNA expression in human area 9 as a function 
of age.  
SST mRNA expression levels are significantly negatively correlated with age in both subject 
groups. The regression line for subjects with schizophrenia (gray line) are parallel to and shifted 
downward from those for control subjects (black line), suggesting that the decreased expression 
of SST mRNA is similar in magnitude across adult life.  
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diagnosis of schizoaffective disorder, history of substance abuse/dependency, use of 
antidepressant medication at time of death, use of benzodiazepines/valproate at time of death, or 
suicide (all t(21) < 1.52, all p > 0.14) (Figure 5). 
In a previous study, the expression of SST mRNA in DLPFC areas 9 and 46 of monkeys did not 
differ among monkeys chronically exposed to haloperidol, olanzapine, or sham (Hashimoto et 
al., 2008a). However, the steady-state trough plasma levels (~1.5 ng/ml) in the haloperidol-
treated monkey group might be considered relatively low compared to levels likely achieved in 
at least some of the subjects with schizophrenia included in this study. Thus, in order to 
determine if chronic exposure to higher levels of haloperidol could affect SST mRNA 
expression, we examined the gray matter of DLPFC areas 9 and 46 from monkeys that received 
haloperidol decanoate for one year with mean trough plasma levels >4 ng/ml (Figure 6). Mean 
(SD) SST mRNA expression did not differ (t(3) = 1.08, p = 0.36) between these haloperidol-
exposed monkeys (275.3 ± 40.3) and their sex-, age-, and weight-matched controls (238.4 ± 
56.1).  
 
Laminar expression patterns of SST mRNA in DLPFC area 9 
In order to determine if the reduction in SST mRNA expression in schizophrenia was selective 
for certain cortical layers, we examined the OD measures by layer (Figure 7). Because of the 
high density of SST mRNA+ neurons in layers 2-superficial 3 (2/3s), these layers were combined 
and distinguished from deep layer 3 (3d). SST mRNA expression was significantly decreased in 
all layers (F(1,40) > 4.34; p < 0.04, for all layers), with the exception of layer 1 (F(1,40) = 0.64; p = 
0.23). Of the layers with a significant diagnostic effect, the largest percentage difference was in 
layer 2/3s (36.6%) and the smallest difference in layer 3d (29.6%). 
 
Cellular levels of SST mRNA expression 
In order to determine if all or a subset of SST cortical neurons were affected, we determined the 
expression level per neuron by counting the silver grains deposited over Nissl-stained neurons in 
layers 2/3s and 5. The mean (± SD) number of grains per positive neuron in layers 2/3s was 
significantly (F(1,40) = 9.72, p = .003) 31% lower in the subjects with schizophrenia (104.4 ± 
49.1) than in the control subjects (150.4 ± 53.4). Similarly, the mean number of grains per 
positive neuron in layer 5 was significantly (F(1,40) = 6.96, p = .012)  decreased by 25% in 
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Figure 5 The effects of potential confounding factors on the expression changes in SST mRNA 
in subjects with schizophrenia.  
The bars represent the mean (SD) percent differences from control subjects for SST mRNA 
within subject pairs, and the numbers within each bar indicate the number of subject pairs. 
Neither sex, diagnosis of schizoaffective disorder, history of substance abuse/dependence, 
history of antidepressant medications, the presence of benzodiazepines/valproate at time of 
death, nor cause of death significantly affected the expression changes in SST mRNA. 
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Figure 6 Representative film autoradiograms illustrating the expression of SST mRNA in the 
dorsal PFC of a control monkey (A) and an age-, sex-, and body weight-matched monkey 
chronically exposed to haloperidol (B).  
The densities of the hybridization signal are presented in a pseudocolor manner according to the 
calibration scale (in A). The signal density appears to be unchanged in the haloperidol-exposed 
monkey (B) relative to the control monkey (A). Solid and dashed lines indicate the pial surface 
and the gray/white matter border, respectively. Open and filled arrowheads indicate the principal 
and cingulate sulci, respectively. 
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Figure 7 Mean (SD) expression levels of SST mRNA by layer as assessed by film 
autoradiography optical density (OD) measures in each cortical layer.  
* p < 0.05, after Holm’s correction. ** p < 0.01, after Holm’s correction. 
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subjects with schizophrenia (121.5 ± 67.3) compared to controls (162.7 ± 45.7) (Figure 8A,B). 
Furthermore, the mean density of SST mRNA+ neurons in layers 2/3s was significantly (F(1,40) = 
10.79, p = .002) decreased by 26% in subjects with schizophrenia (63.3 ± 23.7 neurons/mm
2
) 
relative to control subjects (85.3 ± 16.2 neurons/mm
2
), and in layer 5 was decreased by 23% 
(F(1,40) = 3.93, p = .054) in subjects with schizophrenia (52.5 ± 27.2 neurons/mm
2
) compared to 
control subjects (67.7 ± 15.4 neurons/mm
2
) (Figure 8C,D).  
 
Correlation of altered expression of SST mRNA with changes in other transcripts 
Within-pair percentage differences in SST mRNA expression were significantly correlated (r = 
0.72, p < 0.001; Figure 9A) with those found for GAD67 mRNA expression in a previous study of 
the same subjects (Hashimoto et al., 2005). These reductions in GAD67 mRNA expression in 
schizophrenia were also strongly correlated with changes in the expression of receptor tyrosine 
kinase B (trkB) mRNA, the principal receptor for brain-derived neurotrophic factor (BDNF), and 
to a lesser extent with those in BDNF mRNA expression (Hashimoto et al., 2005). Thus, because 
trkB is expressed in ~50% of SST neurons (Gorba and Wahle, 1999), we examined whether 
reduced BDNF-trkB signaling might be associated with the reduced SST mRNA expression in 
schizophrenia. The within-pair percentage differences in SST mRNA were significantly 
correlated with within-pair percentage differences in both BDNF mRNA expression (r = 0.77, p 
< 0.001; Figure 9B), and trkB mRNA expression (r = 0.74, p < 0.001; Figure 9C).  
 
SST mRNA expression in genetically engineered mice 
We have previously shown that mice with reduced expression of BDNF mRNA exhibit 
decreased SST mRNA expression (Glorioso et al., 2006), suggesting that the correlations 
observed in the human subjects might represent cause and effect. In order to determine if the 
level of trkB mRNA expression also regulates SST mRNA expression, we examined SST mRNA 
expression in the PFC of trkB hypomorphic mice (Xu et al., 2000). Levels of trkB mRNA in the 
frontal cortex of fBZ/+ and fBZ/fBZ genotype mice were decreased by 42% and 75%, 
respectively, as compared to wild-type animals (Hashimoto et al., 2005).  TrkB genotype was 
significantly (F(2,6) = 6.03, p = 0.037) related to the expression level of SST mRNA (Figure 10). 
SST mRNA levels in wildtype mice (596.9 ± 31.4 nCi/g) were significantly greater (p = 0.045) 
than in the fBZ/fBZ genotype (406.3 ± 55.6 nCi/g), and SST mRNA expression in the 
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Figure 8 Cellular SST mRNA measurements in the DLPFC area 9  
of subjects with schizophrenia (gray circles) and control subjects (black circles) as expressed by 
grains per positive neuron (A,B) in layer 2/3s (A) and layer 5 (B) and positive neuron density 
(C,D) in layer 2/3s (C) and layer 5 (D). Subjects in each pair are connected by black lines and the 
mean values for each subject group are indicated by a horizontal line.  
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Figure 9 Correlations of within-subject pair percent differences in SST mRNA expression with 
GAD67 (A), BDNF (B), and TrkB (C) mRNA expression.  
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Figure 10 Representative film autoradiograms illustrating SST mRNA expression in a wild-type 
mouse (A), a mouse heterozygous for the fBZ locus (fBZ/+) (B), and a mouse homozygous for 
the fBZ locus (fBZ/fBZ) (C).  
The arrowheads (apply to all sections) in A indicate the quantified regions in the frontal cortex. 
The densities of hybridization signals are presented in a pseudocolor manner according to the 
calibration scale (below C). D, Bar graph representing mean ± SD of SST mRNA in the PFC in 
each genotype. Bars not sharing the same letter are significantly different (p < .05; post hoc 
Tukey’s multiple comparison).  
40 
fBZ/+ genotype (426.6 ± 110.5 nCi/g) was intermediate, showing a trend to lower values as 
compared to wildtype mice (p = 0.068).  
 
2.5 DISCUSSION 
The expression levels of SST mRNA were significantly decreased in layers 2 – 6 of DLPFC area 
9 in subjects with schizophrenia compared to matched controls; in contrast, SST mRNA 
expression in layer 1 and the white matter did not differ between subject groups. At the cellular 
level, both the density of cortical SST mRNA+ neurons and the expression of SST mRNA per 
neuron were reduced in the subjects with schizophrenia. These alterations appear to reflect the 
disease process of schizophrenia and not to be the consequence of potential confounds. 
Observations in both humans and genetically-engineered mice suggest that these changes are a 
down-stream consequence of impaired neurotrophin signaling in schizophrenia. Together, these 
findings indicate that reduced SST mRNA expression in the DLPFC of subjects with 
schizophrenia is restricted to the gray matter, confined to a subset of SST neurons, and the 
consequence of a plausible pathogenetic mechanism.  
 
Altered SST mRNA expression in schizophrenia is not due to confounds 
Several lines of evidence indicate that the reduction in SST mRNA expression is due to the 
disease process of schizophrenia and is not the result of other factors commonly associated with 
the illness. First, all four subjects with schizophrenia off antipsychotic medications at the time of 
death demonstrated a decrease in SST mRNA expression relative to their matched controls. 
Second, the gray matter expression of SST mRNA was not altered in monkeys chronically 
exposed to plasma levels of haloperidol that produced marked extrapyramidal symptoms 
requiring treatment with benztropine mesylate. Third, SST mRNA expression was unaltered in 
the DLPFC of monkeys chronically exposed to either haloperidol or olanzapine with trough 
plasma levels in the therapeutic range for humans (Hashimoto et al., 2008a). Fourth, neither SST 
mRNA (Marcus et al., 1997) nor protein (Sakai et al., 1995) levels were decreased in the frontal 
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cortex of rats exposed to haloperidol. Furthermore, neither sex, schizoaffective diagnosis, history 
of substance abuse/dependency, treatment with antidepressant medications or 
benzodiazepines/valproate, nor suicide accounted for the decreased expression of SST mRNA in 
the subjects with schizophrenia (see Figure 5). 
A significant negative correlation between age and SST mRNA gray matter expression 
was seen in both controls and individuals with schizophrenia, consistent with previous findings 
of an inverse relationship between age and SST mRNA or protein levels in rat hippocampus and 
monkey frontal cortex (Hayashi et al., 1997; Vela et al., 2003). The regression line for the 
subjects with schizophrenia was parallel to and shifted downward from that of the control 
subjects (Figure 4), indicating that the decreased expression of SST mRNA in the subjects with 
schizophrenia was present across adult life and is, thus unlikely to be a consequence of illness 
chronicity. Furthermore, this observation suggests that the SST mRNA expression deficit is 
present early in the course of the illness and, thus could contribute to the pathophysiology 
underlying the clinical features of the illness. 
 
A subset of SST neurons is affected in schizophrenia  
Our results demonstrate that SST mRNA expression in layers 2 – 6, but not in layer 1 or the 
white matter, was reduced in subjects with schizophrenia. During development of the cerebral 
cortex, early germinal zones proliferate over successive rounds of cell division and give rise to 
post-mitotic migratory neurons. 
3
H-thymidine birth-dating and autoradiographic analyses have 
demonstrated that the earliest generated cells comprise the preplate which, later in development, 
is split into the marginal zone (adult layer 1) and the subplate (adult deep layer 6 and superficial 
white matter) by the later born neurons of the cortical plate (adult layers 2 – superficial 6) 
(Kostovic and Rakic, 1980); (Luskin and Shatz, 1985; Chun and Shatz, 1989a; Bayer and 
Altman, 1990). The combination of birth-dating techniques and immunohistochemistry revealed 
that a subpopulation of the early generated preplate neurons expresses SST (Chun and Shatz, 
1989a). Our data suggest that the early generated SST mRNA+ neurons which reside in layer 1 
and the superficial white matter are not affected in schizophrenia, whereas the later developing 
SST mRNA+ neurons which migrate to the cortical plate are affected. Additional analyses 
support this interpretation. For example, in the rat cortex sublayer 6b also contains residual 
neurons of the embryonic preplate (Valverde et al., 1989), suggesting that SST+ neurons in layer 
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6b might be less affected in schizophrenia than those present in the more superficial layer 6a. 
Consistent with this prediction, the mean decrease in OD measures of SST mRNA in subjects 
with schizophrenia was significantly greater (t(22) = -5.08; p < 0.0001) in the superficial (-37.4 
nCi/g) than in the deep (-14.0 nCi/g) half of layer 6. Given that the cortical plate forms during 
the second trimester of gestation, these findings raise the possibility that the alterations in SST 
neurons reflect the effect of adverse environmental events during that time frame [e.g., maternal 
influenza (Brown, 2006)] that have been associated with an increased risk for schizophrenia. 
However, given how common the alterations in SST neurons appear to be from the present study 
(i.e., 20/23 pairs), other causal factors must also be contributory. For example, both SST and 
parvalbumin-containing cortical GABA neurons are affected in schizophrenia, whereas those 
that contain calretinin appear to be unaffected. Thus, factors shared by SST and parvalbumin 
neurons that differ from calretinin neurons [e.g., place and timing of neuron birth, transcription 
factors regulating cell fate, etc; see (Wonders and Anderson, 2006) for review] might also 
contribute to cell type-specific vulnerability. Of course, other features intrinsic to, or associated 
with the connectivity of, adult SST neurons in layers 2-superficial 6 might contribute to their 
greater vulnerability relative to other SST neurons. 
In both layers 2-superficial 3 and layer 5, we observed a significant reduction in the mean 
density of SST mRNA+ neurons. Similarly, the mean expression level of SST mRNA per neuron 
was significantly reduced. In subjects with schizophrenia, total neuron number in the frontal lobe 
is unchanged (Thune et al., 2001) and the density of nonpyramidal neurons in the DLPFC is 
slightly increased (Selemon et al., 1995) or unchanged (Akbarian et al., 1995). Thus, it appears 
that SST neurons are still present in the DLPFC of subjects with schizophrenia, but that the 
expression of SST mRNA per neuron is reduced, with the reduction so great in some neurons 
that SST mRNA levels fall below the threshold of detection. This pattern of change in SST 
mRNA expression contrasts with the alterations in GAD67 and PV mRNA expression in the 
DLPFC of subjects with schizophrenia. The expression levels of GAD67 mRNA were reduced 
below detectable levels in ~25-35% of GABA neurons, whereas the remaining GABA neurons 
expressed normal levels of GAD67 mRNA, suggesting that a subpopulation of GABA neurons is 
affected in the illness (Volk et al., 2000). The reduced expression of PV mRNA was found to be 
due to a decrease in expression level per neuron rather than to a decrease in the density of PV 
mRNA+ neurons suggesting that most PV mRNA+ neurons are affected (Hashimoto et al., 
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2003). Because the reduction in SST mRNA expression was due to both a decrease in positive 
neuron density and in expression per neuron, these findings suggest that a majority of SST 
neurons express reduced levels of SST mRNA and that a subset of severely affected SST 
neurons express undetectable levels of SST mRNA.  
The severely affected neurons might include the approximately 50% of SST+ neurons 
that express trkB (Gorba and Wahle, 1999), the principal receptor of BDNF. Consistent with this 
interpretation,  mice with genetically engineered reductions in the expression of BDNF mRNA 
have significantly lower levels of cortical SST mRNA and protein (Grosse et al., 2005; Glorioso 
et al., 2006). In addition, the significant reduction in the expression of SST mRNA in the PFC of 
homozygote trkB hypomorphic mice indicates that signaling via trkB is also involved in 
regulating the expression of SST mRNA, even in the face of conserved levels of BDNF. Given 
that the expression levels of BDNF (Weickert et al., 2003; Hashimoto et al., 2005) and trkB 
mRNAs  (Hashimoto et al., 2005; Weickert et al., 2005) are reduced in the DLPFC of subjects 
with schizophrenia, our findings imply that reduced BDNF-trkB signaling in schizophrenia is an 
“upstream” event that contributes to reduced SST mRNA expression. This interpretation is 
consistent with studies demonstrating that the addition of BDNF to cultured cortical cells or the 
intraventricular administration of BDNF in rats increased SST mRNA and protein levels (Nawa 
et al., 1994; Villuendas et al., 2001). Also, previous studies have reported that BDNF can 
influence the expression of GAD67 (Yamada et al., 2002; Cotrufo et al., 2003; Wirth et al., 2003; 
Patz et al., 2004; Palizvan et al., 2004). Therefore, altered BDNF-trkB signaling in schizophrenia 
may be a conserved mechanism driving the highly correlated reductions in SST and GAD67 
mRNA expression in schizophrenia.  
 
Functional implications of alterations in SST neurons in schizophrenia 
In rat and monkey frontal cortex, ~40% of SST neurons also express neuropeptide Y (NPY) 
(Hendry et al., 1984; Kubota et al., 1994). Interestingly, expression deficits in SST and NPY 
mRNAs are strongly correlated in schizophrenia (r = 0.81; p < 0.001) (Hashimoto et al., 2008a) 
and both are similarly reduced in BDNF knockout mice (Glorioso et al., 2006) suggesting that 
the NPY-containing subclass of SST neurons are affected in schizophrenia. Interneurons that 
contain both SST and NPY include the Martinotti cells (Kawaguchi and Kubota, 1997; Reyes et 
al., 1998; Gibson et al., 1999; Ma et al., 2006). The axons of Martinotti cells project to layer 1 
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where they synapse on the apical dendrites of pyramidal neurons and in rodent and monkey 
neocortex, SST interneurons predominately innervate the dendrites of pyramidal neurons 
(Hendry et al., 1984; DeLima and Morrison, 1989; Kawaguchi and Kubota, 1996; Melchitzky 
and Lewis, 2005). Thus, disturbances in the SST/NPY-containing Martinotti class of GABA 
neuron could contribute to the dysfunction of DLPFC circuitry associated with working memory 
impairments in schizophrenia (Weinberger et al., 1986; Goldman-Rakic, 1994; Tan et al., 2005; 
Cannon et al., 2005) through several mechanisms.  
First, in individuals with schizophrenia, disturbances in sensory-gating have been 
correlated with reductions in working memory performance (Silver and Feldman, 2005), 
suggesting that the inability to filter distracting stimuli disrupts working memory. Interestingly, 
in computational modeling of cortical microcircuits and working memory, inhibitory 
interneurons that target the dendritic domain of pyramidal neurons provide resistance against 
distracting stimuli by sending enhanced inhibition to dendrites of nearby pyramidal neurons that 
are selective for other stimuli (Wang et al., 2004a). Furthermore, in rats, high frequency trains 
from pyramidal neurons produce facilitating excitatory  inputs to Martinotti cells that, via 
synapses onto the dendrites of neighboring pyramidal neurons, cause disynaptic inhibition 
(Silberberg and Markram, 2007). Therefore, Martinotti interneurons, by mediating the disynaptic 
inhibition of neighboring pyramidal neurons selective for other stimuli, may filter distracting 
stimuli during working memory tasks. Thus, alterations in SST/NPY-containing Martinotti cells 
in schizophrenia may contribute to altered working memory performance. 
Second, Martinotti interneurons also exhibit low threshold-spiking membrane properties 
(Kawaguchi and Kubota, 1997; Reyes et al., 1998; Gibson et al., 1999; Ma et al., 2006). These 
low threshold-spiking, SST-containing interneurons are extensively electrically coupled into 
networks that robustly synchronize their spiking activity (Gibson et al., 1999; Gibson et al., 
2005) in the theta range (4-7 Hz) producing synchronized inhibitory post-synaptic potentials in 
neighboring pyramidal neurons (Beierlein et al., 2000). Although a direct connection between 
the synchronized theta spiking frequency in these neuronal networks and theta band EEG 
oscillations has not been demonstrated, EEG studies in humans and monkeys have demonstrated 
that theta band EEG oscillations increase in power during working memory tasks (Krause et al., 
2000; Raghavachari et al., 2001; Lee et al., 2005). Furthermore, subjects with schizophrenia 
demonstrate altered frontal theta oscillations during working memory tasks (Schmiedt et al., 
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2005). Thus, disturbances in SST/NPY-containing, low threshold-spiking Martinotti interneurons 
might contribute to alterations in theta oscillations and ultimately to impaired working memory 
performance in subjects with schizophrenia. 
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3.0  DISTINCTIVE GABA-RELATED MRNA EXPRESSION PROFILES IN THE 
DORSOLATERAL PREFRONTAL CORTEX OF SUBJECTS WITH BIPOLAR OR 
MAJOR DEPRESSIVE DISORDER 
3.1 ABSTRACT 
Background. Dysfunction of the dorsolateral prefrontal cortex (DLPFC) in schizophrenia is 
associated with abnormalities in γ-aminobutyric acid (GABA)-containing interneurons. The 
mRNAs for the 67 kDa isoform of glutamic acid decarboxylase (GAD67), an enzyme of GABA 
synthesis, and for somatostatin (SST) and parvalbumin (PV) which are expressed in separate 
subsets of GABA-containing interneurons, exhibit lower expression, whereas the mRNAS for 
the 65 kDa isoform of GAD (GAD65) and calretinin (CR), which is expressed in a third subset of 
interneurons, are unchanged. However, the expression profile of these transcripts have not been 
examined in bipolar disorder (BPD), which shares genetic risk with schizophrenia, and major 
depressive disorder (MDD), which shares environmental consequences of a debilitating 
psychiatric disorder. 
Methods. We used real-time quantitative polymerase chain reaction to assess the levels of 5 
GABA-related transcripts in the DLPFC of 19 matched triads of  subjects with BPD or MDD and 
normal comparison subjects. Results were compared to those from a previous study in 
comparable subjects with schizophrenia. 
Results. Subjects with BPD demonstrated a reduction in PV mRNA expression with no alteration 
in GAD67, GAD65, CR, or SST mRNA expressions; subjects with MDD demonstrated a 
reduction in SST mRNA expression with no alteration in  GAD67, GAD65, CR, or PV mRNA 
expressions. 
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Conclusion. These findings suggest that in the DLPFC the profile of alterations in these GABA-
related transcripts is distinct for each psychiatric population (schizophrenia, BPD, and MDD). 
These profiles may used to explore unique pathogenic mechanisms that may distinguish between 
schizophrenia, BPD, and MDD. 
3.2 INTRODUCTION 
One of the core features in schizophrenia appears to be impairments in cognitive functions 
associated with the dorsolateral prefrontal cortex (DLPFC) and alterations to the circuitry in the 
DLPFC may contribute to these impairments (Weinberger et al., 1986; Goldman-Rakic, 1994; 
Lewis and Lieberman, 2000). Specifically, converging lines of evidence suggest that there are 
disturbances in γ-aminobutyric acid (GABA)-containing interneurons (Lewis et al., 2005). For 
example, reduced amounts of the mRNA and protein for the 67 kDa isoform of glutamate 
decarboxylase (GAD67), an enzyme for GABA synthesis, have been consistently found in the 
DLPFC of individuals with schizophrenia (Akbarian et al., 1995; Mirnics et al., 2000; Guidotti et 
al., 2000; Volk et al., 2000; Straub et al., 2007; Hashimoto et al., 2008c). Furthermore, the 
alterations in inhibitory circuitry appear to implicate specific subsets of GABA neurons. The 
transcripts encoding for parvalbumin (PV) and somatostatin (SST), each of which is expressed in 
separate subsets of GABA neurons, have been found to be robustly decreased, whereas the 
transcript encoding calretinin (CR), which is expressed in a third subset of GABA neurons was 
unchanged in subjects with schizophrenia (Hashimoto et al., 2003; Morris et al., 2008; 
Hashimoto et al., 2008b). In addition, reduced GABA synthesis may be selectively mediated by 
the reductions in GAD67, because mRNA and protein levels of GAD65, an enzyme for GABA 
synthesis during high synaptic demand (Battaglioli et al., 2003), were found to have little to no 
alterations in the DLPFC of subjects with schizophrenia (Guidotti et al., 2000; Hashimoto et al., 
2008c). 
Subjects with bipolar disorder (BPD) (Potash, 2006), but not major depressive disorder 
(MDD), seem to share genetic risks with subjects with schizophrenia. Furthermore, subjects with 
BPD and MDD most likely share several environmental consequences associated with a 
48 
debilitating, persistent psychiatric disorder (e.g. frequent hospitalizations, social isolation). 
Therefore, in order to determine the extent to which the profile of GABA-related mRNA 
expression alterations in schizophrenia is shared with other major psychiatric disorder, we 
utilized real-time qPCR to examine the expression of GAD67, GAD65, CR, PV, and SST mRNAs 
in the DLPFC area 9 of subjects with BPD or MDD. 
3.3 MATERIALS AND METHODS 
Human Subjects 
After consent was obtained from the next of kin, brain specimens were obtained during autopsies 
conducted at the Allegheny County Medical Examiner’s Office (Pittsburgh, PA, USA). Nineteen 
subjects triads, each composed of one subject with bipolar disorder, or major depressive disorder  
and a normal comparison subject matched for sex and as closely as possible for age and post-
mortem interval (PMI) were used in this study (Table 2). Subject groups did not differ in mean 
age, PMI, RNA integrity number (RIN), brain pH, or tissue storage time (for all, F2,54 > 1.04; p > 
0.36) 
An independent committee of experienced research clinicians made consensus DSM IV 
(Diagnosis and Statistical Manual of Mental Disorders) (American Psychiatric Association, 
1994)) diagnoses for each subject based on medical records and the results of structured 
interviews conducted with family members of the deceased as previously described{Glantz, 
2000 3533 /id. All procedures were approved by the University of Pittsburgh’s Committee for 
the Oversight of Research Involving the Dead and Institutional Review Board for Biomedical 
Research. 
 
Tissue Preparation 
As previously described{Volk, 2000 5752 /id}, the right hemisphere of each brain was blocked 
coronally, immediately frozen and stored at -80°C. Cortical gray matter was dissected from 
cryostat sections (20 µm) from the anterior-posterior level corresponding to the middle portion of 
the superior frontal sulcus were cut serially and collected into tubes containing Trizol reagent 
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  Control Subjects  Bipolar Disorder Subjects  
Triad Case Sex/race Age PMI
a pH RIN 
Storage 
Time
b 
Cause of 
death
c Case DSM IV diagnosis Sex/race Age PMI
a pH RIN 
Storage 
time
b 
Cause of 
death
c Medications
d 
1 10003 M/W 49 21.2 6.5 8.4 51 Trauma 1102 
Bipolar Disorder 
NOSg,i,j,l 
M/W 50 12.1 6.7 8.3 61 ASCVD AD, BV, SI 
2 1374 M/W 48 21.7 6.6 7.2 23 
Coronary 
atherosclerotic 
disease 
1121 
Bipolar I 
Disorderg,m 
M/W 40 18.5 6.4 8.3 59 
Pulmonary 
Thromboembolism 
BV, AP 
3 1282 F/W 39 24.5 6.8 7.5 39 ASCVD 957 Bipolar I Disorder F/W 39 22.0 6.7 8.4 83 Drowning AD, SI 
4 1298 M/W 48 24.5 6.5 7.9 36 ASCVD 886 
Bipolar I 
Disorderh 
M/W 45 27.3 7.1 8.3 99 Gunshot to chest  
5 1047 M/W 43 13.8 6.6 9 70 ASCVD 1020 
Bipolar I 
Disorderh,l,m 
M/W 42 6.0 6.7 8.5 74 
Combined drug 
toxicity 
AD, BV 
6 795 M/W 68 12.0 6.8 8.2 115 
Ruptured 
abdominal aortic 
aneurysm 
1130 
Bipolar I 
Disordere,m 
M/W 65 8.9 6.7 8 59 
Carcinoma of 
esophagus 
AD, BV, AP, SI 
7 1318 F/W 58 18.8 6.6 7.4 33 ASCVD 1048 
Bipolar I 
Disorderm 
F/W 51 21.4 6.7 7.7 69 Asphyxiation AD 
8 1324 M/W 43 22.3 6.7 7.3 31 
Dissection of the 
ascending thoracic 
aorta 
697 
Bipolar I 
Disorderm 
M/W 39 25.9 6.6 7.8 133 Exsanguination BV 
9 1444 M/W 46 22.0 6.3 8.4 10 
Pulmonary 
Thromboembolism 
1069 
Bipolar I 
Disordere 
M/W 48 27.2 6.9 8.1 66 ASCVD  
10 1086 M/W 51 24.2 6.6 8.1 64 ASCVD 1244 
Bipolar I 
Disordere,j,l,m 
M/W 52 23.5 6.7 8 45 Asphyxiation AD, BV, AP 
11 1391 F/W 51 7.8 6.6 7.1 20 ASCVD 10004 Bipolar I Disorderl F/W 50 11.7 6.4 8.5 52 
Combined drug 
toxicity 
AP 
12 1196 F/W 36 14.5 6.4 8.2 52 Positional asphyxia 1180 
Bipolar I 
Disorderm 
F/W 28 22.3 6.3 7.5 55 Trauma (jump) AD, SI 
13 1293 F/W 65 18.5 6.5 7.0 38 Trauma 10006 
Bipolar I 
Disorderg,m 
F/W 55 19.0 6.4 8.1 51 Gunshot to head  
14 1153 M/W 55 28.0 6.1 8 57 
Atherosclerotic & 
Hypertensive heart 
disease 
716 
Bipolar I 
Disorderh,j 
M/W 58 27.5 6.8 8.3 130 Gunshot to head  
15 789 M/W 22 20.0 6.8 7.8 117 
Accidental 
Asphyxiation 
1181 
Bipolar I 
Disorderi,l,m 
M/W 28 27.4 6.2 8 55 Morphine toxicity AD, BV, SI 
16 686 F/W 52 22.6 7.1 8.5 135 ASCVD 1328 
Bipolar Disorder 
NOS 
F/W 49 21.5 6.7 7.5 31 
Arrhythmogenic 
sudden cardiac 
arrest 
AD, BV, SI 
17 1247 F/W 58 22.7 6.4 8.4 45 ASCVD 1044 
Bipolar I 
Disorderm 
F/W 56 24.5 6.1 7.1 71 Cardiac arrhythmia AD, BV, AP, SI 
18 1092 F/B 40 16.6 6.8 8.0 64 
Mitral Valve 
Prolapse 
984 
Bipolar I 
Disorderm 
F/W 42 30.8 6.5 8 80 
Combined drug 
overdose 
AD, AP, SI 
19 840e F/W 41 15.4 6.6 9.1 106 ASCVD 945 Bipolar I Disorderf F/W 43 31.8 6.7 7.2 86 Asphyxiation AD, BV, AP, SI 
 Mean  48.1 19.5 6.6 8.0 58     46.3 21.5 6.6 8.0 72   
 SD  10.6 5.1 0.2 0.6 36     9.5 7.3 0.2 0.4 26   
                    
                    
Table 2 Characteristics of Subjects 
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aPMI indicates postmortem interval in hours 
bstorage time (months) at -80°C;  
cASCVD indicates arteriosclerotic cardiovascular disease;  
dindicates prescribed medications at time of death; 
 ealcohol abuse, in remission at time of death;  
falcohol abuse, current at time of death;  
galcohol dependence, in remission at time of death;  
halcohol dependence, current at time of death;  
iother substance abuse, in remission at time of death;  
jother substance abuse, current at time of death; 
kother substance dependence, in remission at time of death; 
lother substance dependence, current at time of death;  
mhistory of psychotic features; 
AD = antidepressants; BV = Benzodiazines/Sodium Valproate; AP = antipsychotics; SI = SSRIs 
 
 Table 2 cont. Characteristics of Subjects  
  Major Depressive Disorder Subjects   
Triad Case DSM IV diagnosis Age PMI
a pH RIN 
Storage 
Time
b 
Cause of 
death
c Medications
d 
1 10010 
Major Depressive 
Disorder
e,m 42 14.3 6.4 7.6 48 
Amitriptyline 
overdose 
AD, BV 
2 1226 
Major Depressive 
Disorder
i,j,k,l,m 44 19.3 6.5 7.5 47 ASCVD  
3 967 
Major Depressive 
Disorder
h 40 22.2 6.6 7.4 81 ASCVD  
4 1053 
Major Depressive 
Disorder 
47 24.0 6.6 8.1 68 ASCVD  
5 1215 
Major Depressive 
Disorder
g 44 11.0 6.5 7.9 50 ASCVD BV 
6 698 
Major Depressive 
Disorder
m 59 13.0 6.6 9.0 132 Hanging AD, AP 
7 1190 
Major Depressive 
Disorder
h 47 22.3 6.6 8.0 53 Asphyxiation  
8 668 
Major Depressive 
Disorder
e,m 34 24.3 6.6 8.1 137 Hanging  
9 863 
Major Depressive 
Disorder 
51 28.3 7.3 8.4 101 ASCVD  
10 1312 
Major Depressive 
Disorder
g,l 51 24.6 6.5 8.1 33 
Combined drug 
toxicity 
 
11 986 
Major Depressive 
Disorder 
53 11.9 6.7 8.7 79 Bronchial asthma AD, SI 
12 1157 
Major Depressive 
Disorder 
26 13.4 6.4 7.8 57 Hanging AD, SI 
13 1041 
Major Depressive 
Disorder
f,l,m 52 10.3 6.5 8.4 71 
Combined drug 
toxicity 
AD, BV, AP, SI 
14 1071 
Major Depressive 
Disorder
e 62 25.6 6.5 8.1 66 Gunshot to trunk  
15 1131 
Major Depressive 
Disorder 
29 26.6 6.9 8.5 59 Gunshot  
16 1143 
Major Depressive 
Disorder
g,l 49 23.4 6.4 8.1 58 
Combined drug 
toxicity 
AD, BV, SI 
17 934 
Major Depressive 
Disorder
m 54 17.9 6.2 8.2 89 ASCVD AD, SI 
18 1289 
Major Depressive 
Disorder 
46 25.0 6.3 7.3 39 ASCVD  
19 1221 
Major Depressive 
Disorder 
28 24.8 6.6 7.2 49 
Pulmonary 
thrombosis 
AD 
 Mean  45.2 20.1 6.6 8.0 69   
 SD  10.1 6.0 0.2 0.5 29   
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(Invitrogen, Carlsbad, CA, USA) for RNA isolation or mounted on Super frost plus glass slides 
(VWR International, West Chester, PA, USA) for Nissl-staining. The location of DLPFC area 9 
was determined from the Nissl-stained sections using cytoarchitectonic criteria as previously 
described (Volk et al., 2000). Total RNA was isolated from Trizol homogenates of sections, 
further purified by RNeasy columns (Qiagen, Valencia, CA, USA) and RNA integrity was 
assessed by measuring RIN (Imbeaud et al., 2005) using the Bioanalyzer 2100 (Agilent 
Technologies, Walbronn, Germany). For all subjects used in this study, RIN was ≥ 7.0. 
 
Real-time qPCR 
For the five GABA-related transcripts, real-time qPCR analyses (Glorioso et al., 2006) were 
performed on DLPFC samples from the subject triads. Using 50 ng of total RNA, cDNA 
synthesis by random primers and SuperScript II reverse transcriptase (Invitrogen) was 
conducted. All primer pairs used (Table 3) exhibited high amplification efficiency (> 97%) in 
the standard curve analysis and specific single products in dissociation curve analysis. After 
primer validation, the comparative threshold cycle (Ct) measurement was performed for 
quantification using SYBR Green I Dye (Applied Biosystems, Foster City, CA, USA) and 
Stepone Plus Real-time PCR instrument (Applied Biosystems) according to the manufacturer’s 
instructions. Each qPCR run included the three subjects in a triad and amplified all 8 transcripts 
of interest in quadruplicate using a plate with 96 wells (3 subjects x 8 transcripts x 4 
replications). Three internal control transcripts encoding for beta-actin, cyclophilin A, and 
glyceraldehyde-3-phosphate dehydrogenase were amplified for each subject. These internal 
control transcripts were selected based on their stable expression across subjects with 
schizophrenia as previously described(Hashimoto et al., 2008c). Furthermore, the internal control 
transcripts were stably expressed across our subject groups regardless of diagnosis (Table 4). 
The difference in cycle threshold for each GABA-related transcript was calculated by subtracting 
the mean cycle threshold for the three internal controls from the cycle threshold of each GABA-
related transcript. This difference in cycle threshold (dCt) represents the log2-transformed 
expression ratio of each GABA-related transcript to the geometric mean of the three internal 
control transcripts (Vandesompele et al., 2002); therefore, the relative expression level of each 
GABA-related transcript was determined as 2
-dCt
. 
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Table 3 Primer pairs and efficiency of amplified gene products 
Gene Accession Size (position) Forward primer Reverse primer Ex 
Beta actin (ACTB) NM_001101 
 
73 bp (23-95) 
 
AGCCTCGCCTTTGCCGA 
 
GCGCGGCGATATATCATCATC 
 
0.97 
 
Cyclophilin (CYC) NM_021130 
 
126 bp (159-284) 
 
GCAGACAAGGTCCCAAAG 
 
GAAGTCACCACCCTGACAAC 
 
0.98 
 
glyceraldehyde-3-
phosphate 
dehydrogenase 
(GAPDH) 
NM_002046 
 
87 bp (556-642) 
 
TGCACCACCAACTGCTTAGC 
 
GGCATGGACTGTGGTCATGAG 
 
0.97 
 
67 kDa glutamate 
decarboxylase 
(GAD67) 
NM_000817 
 
 
86 bp (2495-
2580) 
 
GTTTCCCGCTCCAAGAGAAT 
 
TGGAGTTGTTGGACAAGCTG 
 
1.09 
 
65 kDa glutamate 
decarboxylase 
(GAD65) 
NM_000818 
 
105 bp (177-281) 
 
GTCGGAAGATGGCTCTGG 
 
AGGGCGCACAGTTTGTTT 
 
0.98 
 
Parvalbumin (PV) NM_002854 
 
140 bp (111-250) 
 
GCTACCGACTCCTTCGAC 
 
ATGAATCCCAGCTCATCC 
 
1.00 
 
Somatostatin (SST) NM_001048 
 
93 bp (319-411) 
 
ATGCCCTGGAACCTGAAGAT 
 
CCATAGCCGGGTTTGAGTTA 
 
1.07 
 
Calretinin (CR) NM_001740 
 
145 bp (395-539) 
 
AGCGCCGAGTTTATGGAG 
 
GGGTGTATTCCTGGAGCTTG 
 
1.05 
 
Ex (primer efficiency): Ex is defined by Rn = Ro*(1+Ex)n. Rn = amplification signal of target molecules at cycle n, Ro = initial signal, n = 
number of cycles. For all primer sets, PCR thermal cycling was 10 min polymerase activation at 95°C followed by 40 cycles at 95°C for 15 
sec and 62°C for 1 min.  
 
 
53 
Table 4 Internal Control Ratios 
 
 
 
*The mean 2
-dCt
 relative expression values for beta actin (AB), glyceraldehyde-3-phosphate dehydrogenase (GAP), and Cyclophilin 
(Cyc) 
 
Control (mean ± 
SD)* 
BPD (mean ± SD)* MDD (mean ± SD)* F2,49 value p-value 
AB/GAP 0.81 ± 0.091 0.80 ± 0.086 0.81 ± 0.056 0.016 0.98 
Cyc/AB 0.48 ± 0.054 0.47 ± 0.040 0.47 ± 0.043 0.17 0.85 
GAP/Cyc 2.62 ± 0.38 2.67 ± 0.23 2.65 ± 0.27 0.032 0.97 
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Statistical Analysis 
To determine the diagnosis-related expression differences of each GABA-related transcript, we 
utilized an analysis of covariance (ANCOVA) model with SPSS (SPSS, Inc., Chicago, IL). The 
data were averaged across the four replicates and transformed into relative expression levels (2
-
dCt
) in order for intuitive plots of data (i.e. higher values represent larger relative expression). 
Confirmation of the 2
-dCt
 values for normal distribution within each subject group was 
determined before statistical analyses were performed. The ANCOVA model was performed 
with a main effect of diagnostic group and covariates of sex, age, PMI, RIN, brain pH, and 
storage time. Storage time as a covariate was not significant the model and, thus, was excluded 
in the reported analyses. Multiple comparisons were controlled by adjusting for simultaneous 
inference of significance levels using the Bonferroni-Holm method (Volk et al., 2000) in which p 
values are ordered from the smallest (i = 1) to the largest (i = N) among multiple comparisons; 
the significance level for each comparison is defined as α=0.05/([N+1]-i). For PV mRNA 
analysis, a Tukey’s multiple comparison test was used in post-hoc comparisons across diagnostic 
groups. However, because the effect of age on SST mRNA expression was significant and post-
hoc analyses do not take cofactors such as age into account, we performed 2 separate ANCOVAs 
in which control subjects and subjects with BPD or subjects with MDD were included. 
The influences of potential confounding variables on the relative expression values in 
each diagnostic group were assessed with ANCOVA models using each confounding variable as 
the main effect and sex, age, postmortem interval, pH, and RIN as covariates. Correlations 
between age and mRNA expression were assessed by Pearson’s correlation analyses. 
 
 
3.4 RESULTS 
Alterations in GABA-related transcripts across subject groups 
In order to determine the profile of expression in 5 different GABA-related transcripts in the 
DLPFC of subjects with BPD or MDD, the expression levels of GAD67, GAD65, CR, PV, and 
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SST were quantified by real-time qPCR in 19 subject triads. The primer sets for all the GABA-
related and internal control transcripts have been previously used (Hashimoto et al., 2008c) with 
the exception of CR (Table 3). The rank order of the mean relative expression levels of each of 
the GABA-related transcripts in normal control subjects closely matched previously reported 
rank order of mean expression levels of these mRNAs (Hashimoto et al., 2008c) with SST and 
GAD67 having the highest levels of expression, CR and PV having the lowest levels of 
expression, and GAD65 having an intermediate level of expression (Figure 11). Furthermore, in 
normal control subjects SST mRNA expression was robustly and significantly correlated with 
age (r = -0.86; p < 0.00001) (Figure 12). 
The expression profile of the GABA-related transcripts for each subject group is shown in Figure 
11. Across the three subject groups, the mean levels of GAD67, GAD65, and CR mRNA were 
comparable and, consequently, diagnosis did not significantly effect the expression of these 
transcripts (F2,49 = 0.56, p = 0.57; F2,49 = 0.91, p = 0.82; F2,49 = 2.15, p = 0.38, respectively.  
The expression level of PV mRNA was significantly reduced in subjects with BPD. There was a 
significant effect of diagnosis on the mean expression levels of PV mRNA which remained after 
adjustment for multiple comparisons (F2,49 = 10.73; adjusted p < 0.001). Post-hoc analysis 
revealed a significant reduction in mean PV mRNA expression in subjects with BPD as 
compared to normal control subjects (18%; p=0.004) or to subjects with MDD (20%, p = 0.001), 
but no significant difference between normal control subjects and subjects with MDD (p = 0.88). 
Qualitative examination of the data suggested that, at least in subjects with MDD, there was 
significant reduction in SST mRNA expression. However, there was only a trending effect of 
diagnosis on mean expression levels of SST mRNA (F2,49 = 2.76; p = 0. 07) that did not remain 
after correction for multiple comparisons (adjusted p = 0.30). However, because of the large 
standard deviation in SST mRNA expression due to correlation with age (Figure 12) and the 
inability of post-hoc analyses to correct for covariates (i.e. age), we also performed 3 separate 
ANCOVA comparisons with normal control subjects and subjects with BPD or MDD. When 
compared to normal comparison subjects, there was a trending effect of diagnosis on the mean 
expression level of SST mRNA in subjects with bipolar disorder (-14%; F1,31 = 3.34; p = 0.08) 
and a significant effect of diagnosis on the mean expression level of SST mRNA in subjects with 
MDD (-18%; F1,31 = 9.31; p = 0.005); however, there was no significant effect of diagnosis on 
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SST mRNA expression when subjects with BPD were compared to subjects with MDD (F1,31 = 
0.604; p = 0.85). 
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Figure 11 GABA-related Transcript Expression Levels Across Three Subject Groups.  
The 2
-dCt
 relative expression values are shown for each subject (circles). For each transcript, the 
mean   2
-dCt
 relative expression values are shown for each subject group (black hash marks). The 
statistics (top of graph) represent the effect of diagnosis for each GABA-related transcript. For 
correction of multiple comparisons, the Bonferroni-Holm p-values are given as “adjusted” p-
values (top of graph). PV transcript expression was significantly reduced in subjects with BPD 
before and after correction for multiple comparisons. Effect of diagnosis for SST transcript 
expression reached trending expression that did not remain after correction for multiple 
comparisons. 
*post-hoc Tukey’s multiple comparison test p-values 
**p-values for the effect of diagnosis from one-way ANCOVAs between the subject groups 
indicated 
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Figure 12 The 2
-dCt 
Relative Expression Values of SST mRNA in Human Area 9 as a Function 
of Age.  
Expression levels of SST mRNA are significantly correlated with age in normal control subjects 
(r=-0.86; p=<0.00001), but not in subjects with BPD (r=-0.09; p=0.72) or MDD (r=-0.39; 
p=0.10). 
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Potential Effect of other Factors on GABA-related Transcript Expression 
In the first ANCOVA model of SST mRNA expression which included all three subject groups, 
age was a significant (F1,49 = 10.69; p <0.01) determinant of mean expression levels. Further 
examination revealed that normal control subjects had a significant correlation between age and 
SST mRNA expression (r = -0.86; p < 0.00001); in contrast, both subjects with BPD (r=-0.09; 
p=0.72) and MDD (r = -0.39; p = 0.10) did not have significant correlations between age and 
SST mRNA expression (Figure 12). 
The effects of potential confounding factors on trending or significantly altered GABA-
related transcript expression are shown in Figure 13. We compared the mean expression of PV 
mRNA in subjects with BPD (Figure 13A) and the mean expression of SST mRNA in subjects 
with BPD (Figure 13B) or MDD (Figure 13C) as a function of sex, death by suicide, 
antidepressant medication use at time of death (ATOD), use of benzodiazepines or sodium 
valproate ATOD, antipsychotic medication use ATOD, diagnosis of substance abuse or 
dependence ATOD, use of selective serotonin reuptake inhibitors (SSRIs) ATOD, or history of 
psychosis.  
A majority of the potential confounding factors did not significantly affect transcript 
expression in the relevant subject group. However, perhaps by chance due to the large number of 
comparisons without multiple comparison corrections, a few of the potential confounds had a 
statistically significant effect on transcript level. In order to determine if these confounding 
effects were driving the reductions we saw in transcript levels, we performed ANCOVAs in 
which we restricted our examination to diagnostic subjects that did not have the relevant 
confound and their matched normal comparison subject. These comparisons are shown in Figure 
14. Even with the reduced power of these comparisons, all but one transcript alteration remained 
either trending or significant. When we restricted our examination of SST mRNA expression to 
subjects with BPD that did not take SSRIs ATOD and their matched normal comparison subjects 
(n = 10 pairs), there was no significant effect of diagnosis on mean SST mRNA levels (Figure 
14C) suggesting the trending reduction of SST mRNA expression in subjects with BPD is due to 
usage of SSRI medication. 
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Figure 13 The Effects of Confounding Factors in Diagnostic Groups with Trending or 
Significantly Altered GABA-related Transcripts.  
The effects of sex, suicide, antidepressant medication use at the time of death (AD ATOD), use 
of benzodiazepines or sodium valproate at the time of death (Benz/Val ATOD), antipsychotic 
medication use at the time of death (Antipsych ATOD), diagnosis of substance abuse or 
dependence at the time of death (SA/SD ATOD), use of selective serotonin reuptake inhibitors at 
the time of death (SSRI ATOD), and a history of psychosis are evaluated for PV mRNA 
expression in subjects with BPD (A), SST mRNA expression in subjects with BPD (B), and SST 
mRNA expression in subjects with MDD (C). Mean (hash mark) and individual (circle) 2
-dCt
 
relative expression values are grouped by potential confounding factors. Note the varying scales 
for the Y-axis between (A) and (B or C). Numbers below circles indicate the number of subjects 
in each diagnostic group for each category. 
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3.5 DISCUSSION 
In this study, we examined the profile of expression alterations in 5 GABA-related  mRNA in the 
DLPFC area 9 of two psychiatric populations (BPD and MDD) which we have previously 
characterized in subjects with schizophrenia (Hashimoto et al., 2008c). With the exception of 
CR, our primer sets have been used in a previous study (Hashimoto et al., 2008c) examining the 
expression levels of these GABA-related transcripts in subjects with schizophenia; the rank-
order of expression levels for each GABA-related mRNA in the normal control subject group 
was comparable to previously reported rank-order of expression levels in a separate normal 
control subject group (Hashimoto et al., 2008c). In addition, in normal control subjects SST 
mRNA expression was robustly correlated with age (Figure 12) confirming previously reported 
correlations between age and SST mRNA or protein expression in the rat (Vela et al., 2003), 
monkey (Hayashi et al., 1997), and human (Morris et al., 2008). These data suggest that the 
expression levels of the GABA-related transcripts in this study are reliable and comparable to 
previously reported expression levels validating our decision to measure mRNA expression with 
reverse transcriptase qPCR.  
In subjects with BPD, the expression of GAD67, GAD65, and CR mRNAs were not 
significantly altered in DLPFC area 9. In addition, PV mRNA expression was significantly 
decreased in subjects with BPD when compared to either normal control subjects or subjects 
with MDD. There was a trending reduction in SST mRNA expression in subjects with BPD as 
compared to normal control subjects; however, this alteration is likely due to an effect of SSRI 
usage at time of death (Figure 14C). In subjects with MDD, the expression of GAD67, GAD65, 
CR, and PV mRNAs were not significantly altered in DLPFC area 9. Furthermore, in subjects 
with MDD SST mRNA expression was significantly reduced when compared to normal controls 
subjects. In contrast to these results, our previous study (Hashimoto et al., 2008c) demonstrated a 
distinctly different profile of GABA-related alterations in the DLPFC area 9 of subjects with 
schizophrenia in which the expression of CR mRNA was not significantly altered; however, 
there were robust reductions in GAD67, PV, and SST mRNAs and a smaller reduction in GAD65 
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mRNA.  Together, these findings indicate that the profiles of alterations in GABA-related 
transcripts found in the DLPFC of subjects with BPD, MDD, or schizophrenia are distinct from 
one another. 
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Figure 14 GABA-related Transcript Expression Levels after Removal of Subject Pairs with 
Potential Confounding Factors.  
The mean (hash mark) and individual (circle) 2
-dCt
 relative expression values are plotted by 
diagnostic group for PV mRNA (A) and SST mRNA (B, C, and D). Note the varying scales for 
the Y-axis between (A) and (B, C, and D). Subjects with BPD that had antipsychotic medication 
use at the time of death and their matched controls were removed and the subjects with BPD (n = 
12) demonstrated a trending reduction in PV mRNA expression (A). Subjects with MDD that 
were using benzodiazepines or sodium valproate at the time of death and their matched control 
subjects were removed and the subjects with MDD (n = 15) demonstrated a significant reduction 
of SST mRNA expression (B). Subjects with BPD (C) or MDD (D) that were using selective 
serotonin reuptake inhibitors at the time of death and their matched control subjects were 
removed and the subjects with MDD (n = 14) demonstrated a significant reduction of SST 
mRNA expression (D) while the subjects with BPD (n = 10) did not demonstrate a significant 
alteration in SST mRNA expression (C). 
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Several lines of evidence indicate that the reduction in PV mRNA expression in subjects with 
BPD is not a consequence of factors frequently associated with the illness. PV expression is not 
altered by chronic antipsychotic treatment in several animal models. For example, PV mRNA 
expression was not altered in the PFC of monkeys with long-term exposure to high plasma levels 
of haloperidol, which produced marked extrapyramidal symptoms and required treatment with 
benztropine mesylate (Hashimoto et al., 2003); furthermore,  PV expression was reported to be 
increased (Scruggs and Deutch, 1999) or not altered (Cahir et al., 2005) in the frontal cortex of 
mice that were chronically treated with either haloperidol or clozapine. Additionally, when we 
compared subjects with BPD that were not medicated with antipsychotics ATOD to their 
matched controls there remained a trending reduction in PV mRNA expression (Figure 14A). 
Furthermore, alterations in PV mRNA expression was not associated with death by suicide, use 
of antidepressant medication, benzodiazepines, valproate, or SSRIs at time of death, diagnosis of 
substance abuse or dependency at time of death, or a history of psychosis (Figure 13A). These 
data suggest that the reduction in PV mRNA is associated with the disease process of BPD, or at 
least not a consequence of other factors commonly associated with the illness. 
Converging lines of evidence suggest that the significant reduction in the expression of 
SST mRNA in subjects with MDD is related to the disease process. The use of benzodiazepines 
or valproate at time of death in subjects with MDD was associated with lower expression of SST 
mRNA (Figure 13C). However, benzodiazepine or valproate use at time of death is not 
associated with significant alterations SST mRNA expression in the DLPFC of subjects with 
schizophrenia (Morris et al., 2008) or subjects with BPD (Figure 13A). Consistent with these 
data, chronic administration of diazepam did not significantly alter SST protein levels in rat 
frontoparietal cortex (Martinez-Ferrer et al., 2000). Furthermore, there was a significant 
reduction in SST mRNA in subjects with MDD that were not using benzodiazepines or valproate 
at time of death compared to their matched control subjects (Figure 14B). The use of SSRIs at 
time of death in subjects with MDD was associated with lower expression of SST mRNA. This 
association is also seen in subjects with BPD (Figure 13B) suggesting that SSRIs may influence 
SST mRNA expression. However, when subjects with MDD that were not using SSRIs at time 
of death were compared to their matched control subjects there was a significant reduction in 
SST mRNA expression (Figure 14D). Additionally, the alterations in SST mRNA expression in 
subjects with MDD were not associated with death by suicide, use of antidepressant medication 
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at time of death, diagnosis of substance abuse or dependency at time of death, or a history of 
psychosis. Together, these data suggest that the reduction in SST mRNA expression is associated 
with the disease process of MDD and not due to other common factors associated with the 
illness. 
 
Effect of SSRIs on SST mRNA Expression 
The trending reduction in SST mRNA expression in subjects with BPD was associated with the 
use of SSRIs at time of death (Figure 13B). Further examination of subjects with bipolar 
disorder that were not using SSRIs at time of death did not demonstrate a significant alteration in 
SST mRNA expression when compared to their matched control subjects (Figure 14C) 
suggesting that the trending alteration in SST mRNA expression in subjects with BPD is 
associated with SSRI use. Subjects with MDD also demonstrated a significant interaction of 
SSRI use on the expression of SST mRNA expression (Figure 13C) consistent with the 
hypothesis that SSRI use alters SST mRNA expression. Interestingly, in normal control subjects 
the expression of SST mRNA expression was robustly correlated with age (Figure 12); this 
correlation was not apparent in either subject group suggesting that a third factor such as SSRI 
usage may be influencing SST mRNA expression. These data suggest an interaction between 
SSRI usage and levels of SST mRNA in the DLPFC; however, further verification in animal 
models is needed to confirm this hypothesis. 
 
GAD67 Transcript Expression in BPD 
We did not observe an alteration in the expression of GAD67 mRNA in the DLPFC of subjects 
with BPD. In contrast, previous studies have demonstrated reduced GAD67 protein in the DLPFC 
of subjects with BPD (Guidotti et al., 2000) and reduced GAD67 mRNA+ neuron density in the 
DLPFC area 9 in subjects with BPD (Woo et al., 2008). In both of the studies, the reduction in 
GAD67  was found only in subjects with BPD that had a history of psychosis. When examination 
of the effect of a history of psychosis in subjects with BPD (n=11) did not reveal any effect on 
GAD67 mRNA expression; however, it is possible that we did not have enough power to detect 
any significant effect. 
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The distinct GABA-related neuropathologies found in each of these subject groups may arise 
from disparate upstream mechanisms; alternatively, the GABA-related neuropathology found in 
schizophrenia is a culmination of one or more upstream mechanisms common to either BPD 
and/or MDD. 
 
In subjects with BPD, there was a reduction in PV mRNA expression with no change in GAD67 
mRNA expression suggesting that it is not due to a common factor that may induce both a 
decrease in PV and GAD67 mRNA. Instead, this reduction could reflect alterations in 
transcriptional regulation secondary to the genetic liability for the illness. For example, the PV 
gene lies in the vicinity of the marker D22S278 (GenBank NT_011520) a putative susceptibility 
gene for bipolar disorder as well as schizophrenia (Schwab and Wildenauer, 2000). 
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4.0  NPY MRNA EXPRESSION IN THE PREFRONTAL CORTEX: SELECTIVE 
REDUCTION IN THE SUPERFICIAL WHITE MATTER OF SUBJECTS WITH 
SCHIZOAFFECTIVE DISORDER 
4.1 ABSTRACT 
Background. Alterations in the inhibitory circuitry of the dorsolateral prefrontal cortex (DLPFC) 
in schizophrenia include reduced expression of the messenger RNA (mRNA) for somatostatin 
(SST), a neuropeptide present in a subpopulation of γ-aminobutyric acid (GABA) neurons.  
Neuropeptide Y (NPY) is expressed in a subset of SST-containing interneurons and lower levels 
of NPY mRNA have also been reported in schizophrenia spectrum disorders. However, whether 
the alterations in these two transcripts identify the same, particularly vulnerable, subset of 
GABA neurons has not been examined.  
Methods. We used in situ hybridization to quantify NPY mRNA levels in DLPFC gray and white 
matter from 23 pairs of subjects with schizophrenia or schizoaffective disorder and matched 
normal control subjects; results were compared to those from a previous study of SST mRNA 
expression in the same subjects.  
Results. In contrast to SST mRNA, NPY mRNA levels were not significantly lower in the gray 
matter of subjects with schizophrenia or schizoaffective disorder. However, NPY, but not SST, 
mRNA expression was significantly lower in the superficial white matter of subjects with 
schizoaffective disorder.  
Conclusion. These findings suggest that the alterations in SST-containing interneurons in 
schizophrenia and schizoaffective disorder are selective for the subset that do not express NPY 
mRNA, and that lower NPY mRNA expression in the superficial white matter may distinguish 
subjects with schizoaffective disorder from those with schizophrenia. 
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4.2 INTRODUCTION 
Alterations in the inhibitory circuitry of the dorsolateral prefrontal cortex (DLPFC) appear to be 
a common feature of schizophrenia (Torrey et al., 2005; Akbarian and Huang, 2006). For 
example, lower levels of the mRNA that encodes for the 67 kDa isoform of glutamic acid 
decarboxylase (GAD67), an enzyme for GABA synthesis, have been consistently found in the 
DLPFC of individuals with schizophrenia (Akbarian et al., 1995; Mirnics et al., 2000; Guidotti et 
al., 2000; Volk et al., 2000; Hashimoto et al., 2005; Straub et al., 2007); this decrease is due to a 
marked reduction in GAD67 mRNA expression in a minority (~25-35%) of GABA neurons, with 
apparently normal levels of expression in the remaining neurons (Akbarian et al., 1995; Volk et 
al., 2000). The affected neurons include the GABA neurons that express the calcium-binding 
protein, parvalbumin (PV) (Hashimoto et al., 2003), or the neuropeptide, somatostatin (SST) 
(Morris et al., 2008), whereas the ~50% of GABA neurons that express calretinin (CR) appear to 
be unaffected (Woo et al., 1998; Hashimoto et al., 2003; Sakai et al., 2008).  
In the frontal cortex of rodents, ~40% of SST neurons also express NPY and most NPY 
neurons contain SST (Hendry et al., 1984; Kubota et al., 1994). Both SST (Morris et al., 2008) 
and NPY (Caberlotto et al., 2000) mRNAs are expressed by neurons in the gray and white matter 
of the human DLPFC. Some studies have found lower levels of NPY mRNA (Mellios et al., 
2008; Hashimoto et al., 2008a) or protein (Gabriel et al., 1996) in homogenates containing both 
gray and white matter from the DLPFC of subjects with schizophrenia or schizoaffective 
disorder, suggesting that the NPY-containing subclass of SST neurons is preferentially affected 
in these illnesses (Morris et al., 2008). However, we found that lower SST mRNA expression in 
schizophrenia was restricted to cortical layers 2-superficial layer 6 (Morris et al., 2008), whereas 
most NPY mRNA expression in the human cortex is located in deep layer 6 and the superficial 
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white matter (Caberlotto et al., 2000). Consistent with these observations, the co-localization of 
SST and NPY mRNAs in the rodent cerebral cortex is most prominent in layer 6 and is 
uncommon in the superficial layers (Wang et al., 2004b).  
Consequently, in order to determine if the levels of NPY and SST mRNAs are altered in the 
same or different populations of DLPFC neurons, we used in situ hybridization and 
autoradiographic analyses to quantify NPY mRNA expression in the gray and white matter 
compartments of DLPFC area 9 from 23 pairs of subjects with schizophrenia or schizoaffective 
disorder and matched normal control subjects in which we had previously measured SST mRNA 
expression using an identical approach (Morris et al., 2008). 
 
4.3 MATERIALS AND METHODS 
Human subjects. Brain tissue specimens were obtained from the Allegheny County Medical 
Examiner’s Office at the time of autopsy with the consent of the next-of-kin. Subjects with 
schizophrenia (n = 15) or schizoaffective disorder (n = 8) were each matched with one normal 
control subject for sex, and as closely as possible for age and postmortem interval (PMI) (Table 
2). Subject groups did not differ in mean age, PMI, brain pH, RNA integrity number (RIN), or 
tissue storage time at -80
0
 C (for all t < 1.61; p > 0.11). Additional demographic and clinical 
details are provided in our previous study of SST mRNA expression in this subject cohort 
(Morris et al., 2008). An independent committee of experienced research clinicians made 
consensus DSMIV (Diagnosis and Statistical Manual of Mental Disorders (American Psychiatric 
Association, 1994)) diagnoses based on structured interviews conducted with family members of 
the deceased and a review of medical records. All procedures were approved by the University of 
Pittsburgh’s Institutional Review Board for Biomedical Research and Committee for Oversight 
of Research Involving the Dead. 
 
Tissue preparation. For each brain specimen, coronal blocks from the right frontal cortex were 
immediately frozen and stored at -80°C. Serial sections (20 μm) containing the superior frontal 
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gyrus were cut on a cryostat, thaw-mounted onto glass slides and stored at -80°C until processed. 
Adjacent sections were collected into tubes containing Trizol (Invitrogen Corp, Carlsbad, CA) in 
order to obtain RNA for RIN measures using the Agilent Bioanalyzer 2100 (Agilent 
Technologies, Inc., Santa Clara, CA) according to the manufacturer’s protocol as previously 
described (Hashimoto et al., 2008a). The location of DLPFC area 9 was identified by 
cytoarchitectonic criteria in Nissl-stained sections as previously described (Glantz et al., 2000; 
Volk et al., 2000; Volk et al., 2001). Three sections per subject, at intervals of approximately 300 
µm, were matched for anterior-posterior location within subject pairs, and used to assess NPY 
mRNA expression. 
 
 In situ hybridization. Templates for the synthesis of the antisense and sense riboprobes for 
human NPY mRNA were first generated by polymerase chain reaction (PCR). The specific 
primers amplified a 430 base pair fragment of human NPY. These fragments corresponded to 
bases 34-463 of the human (GenBank NM_000905) NPY gene. Nucleotide sequencing 
confirmed 100% homology of the amplified fragment to the previously reported sequence. The 
fragment was then subcloned into a plasmid (pSTBlue-1, Novagen, Madison, WI). The antisense 
and sense riboprobes were transcribed in the presence of 
35
S-CTP (Amersham Biosciences, 
Piscataway, NJ) using T7 and SP6 RNA polymerase, respectively. DNase I was used to digest 
the DNA template. The riboprobes were purified using RNeasy mini spin columns (Qiagen, 
Valencia, CA). 
For each matched subject pair, one section from each pair was processed side-by-side in 
three separate runs. Prior to the hybridization reaction, tissue sections were fixed with 4% 
paraformaldehyde in PBS solution, acetylated with 0.25% acetic anhydrate in 0.1 M 
triethanolamine/0.9% NaCl for 10 minutes, dehydrated with a graded alcohol series, and then 
defatted in chloroform for 10 minutes. The sections were then hybridized with 
35
S-labeled 
riboprobes (2.0 X 10
6
 cpm/μl) in hybridization buffer at 56°C for 16 hours. The hybridization 
buffer contained 50% formamide, 0.75 M NaCl, 20 mM 1,4-piperazine diethane sulfonic acid, 
pH 6.8, 10 mM EDTA, 10% dextran sulfate, 5X Denhardt’s solution (0.2 mg/ml Ficoll, 0.2 
mg/ml polyvinylpyrrolidone, 0.2 mg/ml BSA), 50 mM dithiothreitol, 0.2% SDS, and 100 μg/ml 
yeast tRNA. Following the hybridization reaction, sections were washed in a solution of 0.3 M 
NaCl, 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, and 50% formamide at 63°C, treated with 
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RNase A (20 μg/ml) at 37°C, washed in 0.1 X SSC (1.5 mM NaCl, 150 μM sodium citrate) at 
67°C, dehydrated through a graded ethanol series, and air dried. Sections from both subjects in a 
pair were exposed on the same BioMax MR film (Kodak, Rochester, NY) for 4 days, and then 
coated with NTB2 emulsion (Kodak) diluted 2:1 with water. The emulsion was exposed for 9 
days at a constant temperature of 4°C. The slides were developed with D-19 (Kodak) and 
counterstained with Cresyl-violet. 
 
Quantification of mRNA expression levels. Each section was randomly coded, so that subject 
number and diagnosis were unknown to the single rater (RS). Autoradiographic films were trans-
illuminated and captured on video camera under controlled conditions, digitized, and analyzed 
with a Microcomputer Imaging Device (MCID; Imaging Research Inc., London, Ontario, 
Canada) as previously described (Eggan et al., 2008). Digitized images of adjacent Nissl-stained 
sections were superimposed onto autoradiographic images to draw contours of the full cortical 
thickness of the locations in area 9 that were cut perpendicular to the pial surface. Optical density 
measures within each sampled area were calibrated to radioactive Carbon-14 standards (ARC 
Inc., St. Louis, MO), exposed on the same autoradiographic film, and expressed as nanocuries 
per gram (nCi/g) of tissue. The mean (SD) total areas of gray matter sampled for each control 
and schizophrenia subject were 114 (55) mm
2
 and 115 (48) mm
2
, respectively. Optical density 
measures in the superficial white matter were determined in a zone extending 800 μm below, and 
with a contour that followed, the layer 6/white matter border of the sampled gray matter zones. 
The mean (SD) total areas of superficial white matter sampled were 10.7 (5.7) mm
2
 for control 
subjects and 12.9 (5.5) mm
2
 for subjects with schizophrenia. Total white matter was sampled by 
outlining the gray matter/white matter border and including all white matter on the section. The 
mean total areas (SD) of white matter sampled were 95 (39) mm
2 
for control subjects and 105 
(49) mm
2
 for schizophrenia subjects.   
 
Statistical analyses. Two analyses of covariance (ANCOVA) models were used to test 
differences in NPY mRNA expression between control subjects and subjects with schizophrenia. 
The data were averaged across the three sections per subject before statistical analyses. The first 
ANCOVA model used diagnostic group as the main effect, pair as a blocking effect, and storage 
time, brain pH, and RIN as covariates. Brain pH and RIN were included as covariates because 
73 
they may influence mRNA quantity and integrity (Harrison et al., 1995; Stan et al., 2006). The 
pair effect reflects the matching of individual subject pairs for sex, age and PMI. Subject pairing 
may be considered an attempt to balance the two diagnostic groups with regard to the 
experimental factors instead of a true statistical paired design. Thus, to validate the first model, a 
second ANCOVA model was performed with a main effect of diagnostic group and covariates of 
sex, age, PMI, brain pH, RIN, and storage time. Storage time as a covariate was not significant in 
either model and, was excluded in the reported analyses. Both models produced comparable 
results for diagnostic group effect; because age showed trend level effects, the results of the 
second model are reported. 
 The potential influence of history of substance abuse/dependence, diagnosis of 
schizoaffective disorder, medications at time of death, or death by suicide on the within-pair 
percentage of differences in mRNA expression was assessed by two-sample t-test analyses. 
Correlations were assessed by Pearson’s correlation analyses. 
 
4.4 RESULTS 
Specificity of NPY riboprobe. Several lines of evidence confirm the specificity of the riboprobe 
for NPY mRNA used in this study. First, NPY mRNA expression had the distinctive distribution 
previously reported for NPY-containing interneurons in the human frontal cortex (Caberlotto et 
al., 2000). Specifically, NPY mRNA levels were lowest in layer 1, moderate in layer 2, low in 
layers 3-5, and high in layer 6 and the white matter (Figure 15A). Second, the presence of 
intensely NPY mRNA-positive neurons in the superficial and deep white matter (Figure 15A) is 
consistent with previous descriptions of NPY mRNA-positive and immunopositive cell bodies in 
human frontal cortex (Caberlotto et al., 2000). Third, emulsion-coated sections demonstrated 
silver grain clusters over large, faintly Nissl-stained neuronal nuclei, whereas the smaller and 
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Figure 15 Representative film autoradiograms from a normal control subject (A) and matched 
subject with schizoaffective disorder (B).  
The densities of hybridization signals are presented in a pseudocolor manner according to the 
calibration bar. The solid and dashed lines indicate the pial surface and the gray/white matter 
border, respectively. The calibration bar applies to both panels. The expression of NPY mRNA 
in the superficial white matter appears to be lower in the subject with schizoaffective disorder 
(B) relative to the matched control subject (A). 
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more intensely stained glial nuclei lacked silver grains (data not shown). Fourth, sense 
riboprobes for NPY mRNA showed an absence of signal above background (data not shown). 
 
 Expression of NPY in area 9 gray and white matter. The mean (±SD) optical density (OD) of 
NPY mRNA expression in the gray matter did not significantly (F(1,39) = 0.67; p = 0.42) differ 
between the schizophrenia (31.8 ± 9.0 nCi/g) and control (35.0 ± 8.9 nCi/g) groups (Figure 16A). 
Similarly, the mean OD in the total white matter was not significantly different (F(1,39) = 1.41; p 
= 0.242) between the schizophrenia (43.1 ± 13.0 nCi/g) and control (49.3 ± 13.3 nCi/g) groups 
(Figure 16C). In contrast, mean OD in the superficial white matter was significantly reduced 
(F(1,39) = 6.14; p = 0.018) by 19% in the schizophrenia groups (68.6 ± 15.4 nCi/g) relative to the 
control groups (84.3 ± 25.3 nCi/g) (Figure 16B).  
The effect of age on NPY mRNA levels in the superficial white matter showed a trend (F(1,39) = 
3.42; p = 0.072) level of significance. Further analyses revealed that OD measures from 
superficial white matter contours in the schizophrenia groups were not significantly correlated 
with age (r = -0.12; p = 0.58); in contrast, NPY mRNA expression did significantly decline with 
age in control subjects (r = -0.51; p = 0.013). The within-subject pair percent differences in NPY 
mRNA expression in the superficial white matter did not differ as a function of sex, history of 
substance abuse/dependence, or the use of antidepressant medications or 
benzodiazepines/valproate at time of death (all t(21) > -1.68, all p > 0.11) (Figure 17). However, 
the mean within-subject pair percent difference in NPY mRNA expression in the superficial 
white matter was significantly larger for subject pairs with a diagnosis of schizoaffective 
disorder or death by suicide (t(21) = -2.80, p = 0.01 and t(21) = -2.73, p = 0.01, respectively) 
(Figure 17). 
Consistent with the absence of a group difference in SST mRNA levels in the superficial 
white matter
 
(Morris et al., 2008), the within-pair percent differences in NPY mRNA expression 
in the superficial white matter were not significantly correlated (r = 0.006, p = 0.98) with those 
for SST mRNA in the same subjects. 
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Figure 16 NPY mRNA expression levels assessed by autoradiographic film optical density (OD) 
measures in DLPFC area 9 of matched subject pairs for the gray matter (A), superficial white 
matter (B), and total white matter (C).  
Values below the dashed unity line indicate a lower level of NPY mRNA expression in the 
subjects with schizophrenia or schizoaffective disorder relative to their matched control subject. 
The key in (C) applies to all graphs. 
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Figure 17 The effects of potential confounding factors on the expression differences of NPY 
mRNA in the superficial white matter.  
Bars represent the mean (SD) percent differences from control subjects for NPY mRNA within 
subject pairs, and the numbers above each bar indicate the number of subject pairs. Neither sex, 
substance abuse/dependence at time of death, use of antidepressant medications at time of death, 
or use of benzodiazepines/valproate at time of death affected the expression differences. 
However, within-subject pair differences in NPY mRNA expression were significantly greater in 
subjects with a diagnosis of schizoaffective disorder or death by suicide.  
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4.5 DISCUSSION 
The expression of NPY mRNA in the DLPFC of normal control subjects was lowest in layer 1, 
moderate in layer 2, low in layers 3-5, and high in layer 6 and the white matter; this pattern was 
distinctively different from the high levels of SST mRNA in layers 2, superficial 3 and 5 in these 
subjects (Morris et al., 2008). In addition, in contrast to SST mRNA, the expression of NPY 
mRNA in gray matter and total white matter of DLPFC area 9 did not differ between the 
schizophrenia and normal control groups. However, NPY (but not SST) mRNA levels were 
significantly lower in the superficial white matter of the schizophrenia group, a finding that was 
due to markedly lower levels in subjects with a diagnosis of schizoaffective disorder or death by 
suicide. Because suicide was not associated with altered NPY mRNA or protein levels in 
previous studies of the frontal cortex of subjects with psychiatric disorders (Caberlotto and Hurd, 
1999; Klempan et al., 2009), it seems likely that a diagnosis of schizoaffective disorder is the 
primary cause of the lower NPY expression. Finally, the NPY mRNA expression differences in 
the superficial white matter were not correlated with those for SST mRNA in the same subjects. 
Together, these findings indicate that alterations in NPY and SST mRNA expression in 
schizophrenia occur 1) in separate populations of neurons, 2) in distinct compartments of the 
DLPFC, and 3) in different subsets of subjects.  
The finding of lower NPY mRNA levels does not appear to be attributable to 
antipsychotic medications since both subjects with schizoaffective disorder (537 and 829) who 
were off antipsychotic medications at time of death had lower levels of NPY mRNA expression 
in the superficial white matter. Consistent with this interpretation, chronic administration of 
either olanzapine, clozapine, or haloperidol to rats was not associated with reduced NPY mRNA 
expression in the cingulate cortex (Huang et al., 2006).   
Although some studies have reported lower levels of NPY protein and mRNA in the 
frontal cortex of subjects with schizophrenia, these studies evaluated tissue homogenates that 
included both gray and white matter (Gabriel et al., 1996; Mellios et al., 2008; Hashimoto et al., 
2008a) and/or included subjects with schizoaffective disorder (Hashimoto et al., 2008a). Our 
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results clarify these findings by demonstrating that NPY mRNA expression is not altered in 
either the gray or white matter compartments in the DLPFC of subjects with “pure” 
schizophrenia, consistent with another in situ hybridization study of prefrontal gray matter NPY 
expression (Caberlotto and Hurd, 1999), but is reduced in the superficial white matter of subjects 
with schizoaffective disorder. Interestingly, NPY mRNA expression was previously reported to 
be lower in the prefrontal cortex of subjects with bipolar disorder, a mood disorder frequently 
accompanied by psychosis, but not in subjects with schizophrenia or major depressive disorder 
(Caberlotto and Hurd, 1999). These findings, in concert with the results of the present study, 
suggest that NPY mRNA neurons in the superficial white matter may be preferentially 
vulnerable in individuals with severe disruptions in both reality testing and mood regulation.  
The affected NPY-containing neurons are likely the remnants of the earliest born neurons in the 
neocortex. During development of the cerebral cortex, the earliest born cells form the preplate 
which is subsequently split into the marginal zone (adult layer 1) and the subplate (adult deep 
layer 6 and superficial white matter) by later born neurons which migrate to become the cortical 
plate (adult layers 2 – superficial 6) (Kostovic and Rakic, 1980). Interestingly, NPY protein is 
present very early in human development in the preplate neurons underlying DLPFC areas 9 and 
46; and in adult human prefrontal cortex, NPY protein is most strongly expressed by neurons 
located in the residual preplate (layer 1, deep layer 6, and the underlying white matter) (Uylings 
and Delalle, 1997; Delalle et al., 1997). Thus, the vulnerable neurons in subjects with 
schizoaffective disorder, that is those with concurrent psychotic symptoms and a mood disorder, 
appear to be residual preplate neurons. The relatively low expression of NPY mRNA in layer 1 
likely precluded the ability to detect any differences between subjects groups in the residual 
preplate neurons present in this location. However, other markers of layer 1 interneurons that are 
co-localized with NPY do suggest that these neurons are affected in individuals with both 
psychosis and mood alterations. For example, most NPY-containing neurons in layer 1 also 
express reelin mRNA, at least in the adult mouse brain (Alcantara et al., 1998), and both reelin 
protein and mRNA levels are lower in subjects with bipolar disorder with a history of psychosis 
(Guidotti et al., 2000),  although the laminar specificity of this finding was not examined.  
In contrast, the deficits in SST mRNA expression in the DLPFC of subjects with 
schizophrenia were restricted to cortical layers that arise from the cortical plate, and were not 
present in residual preplate neurons (Morris et al., 2008). Together, these findings raise the 
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hypothesis that the phenotypic differences between “pure” schizophrenia and schizoaffective 
disorder may reflect differences in the types of, or timing of exposure to, environmental factors 
that are associated with increased risk for a psychotic illness (Lewis and Levitt, 2002). That is, 
although the liability to schizophrenia and schizoaffective disorder (and psychotic bipolar 
disorder) may arise from shared genetic factors (Potash, 2006), the resulting clinical phenotype 
may reflect the impact of adverse environmental events during development that preferentially 
affect NPY-containing preplate neurons or SST-containing cortical plate neurons. Testing of this 
hypothesis might include the determination of whether the nature of the reported altered density 
[increased in some studies and decreased in others (Akbarian et al., 1996; Eastwood and 
Harrison, 2003; Eastwood and Harrison, 2005)], of neurons in the superficial white matter of a 
subset of subjects with schizophrenia, is associated with a particular clustering of clinical 
features. 
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5.0  SOMATOSTATIN RECEPTOR SUBTYPE 1 AND 2 MRNA EXPRESSION IN 
THE PREFRONTAL CORTEX OF SUBJECTS WITH SCHIZOPHRENIA 
5.1 ABSTRACT 
Background. Alterations in the inhibitory circuitry of the dorsolateral prefrontal cortex (DLPFC) 
in schizophrenia include reduced expression of the messenger RNA (mRNA) for somatostatin 
(SST), a neuropeptide present in a subpopulation of γ-aminobutyric acid (GABA) neurons.  
However, whether the alterations in SST-containing interneurons affect post-synaptic receptors 
for SST has not been examined in the DLPFC of subjects with schizophrenia. In mice, SST 
receptor subtype 1 (SSTR1) and SSTR subtype 2 (SSTR2) are the most abundant of the receptor 
subtypes in the frontal cortex. 
Methods. We used in situ hybridization to quantify SSTR1 and SSTR2 mRNA levels in DLPFC 
area 9 from 23 pairs of subjects with schizophrenia or schizoaffective disorder and matched 
normal control subjects; results were compared to those from a previous study of SST mRNA 
expression in the same subjects. Using in situ hybridization we quantified SSTR2 mRNA 
expression in 2 cohorts of monkeys chronically treated with typical or atypical antipsychotics. 
Results. SSTR1 mRNA levels were not significantly lower in the DLPFC of subjects with 
schizophrenia or schizoaffective disorder. However, SSTR2 mRNA expression was significantly 
lower in the DLPFC of subjects with schizophrenia or schizoaffective disorder. Furthermore, 
there was an effect of chronic haloperidol exposure on SSTR2 mRNA expression in monkey 
frontal cortex that did affect our results. 
Conclusion. These findings suggest that the reduction in both SST and SSTR2 mRNA 
expression in schizophrenia and schizoaffective disorder provide converging reductions in 
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inhibitory drive which may be a result of a compensation for a common “upstream” event such 
as reductions in excitatory drive at the dendritic domain of pyramidal neurons.  
 
Keywords: GABA, interneurons, typical, antipsychotic, dendrite 
5.2 INTRODUCTION 
Many converging lines of evidence suggest that alterations in specific subpopulations of 
inhibitory neurons of the dorsolateral prefrontal cortex (DLPFC) is a common feature of 
schizophrenia (Torrey et al., 2005; Akbarian and Huang, 2006). Evidence of this is demonstrated 
by lower levels of the mRNA that encodes for the 67 kDa isoform of glutamic acid 
decarboxylase (GAD67) in a minority (~25-35%) of GABA neurons, with apparently normal 
levels of expression in the remaining neurons (Akbarian et al., 1995; Volk et al., 2000). The 
affected neurons include the GABA neurons that express the calcium-binding protein, 
parvalbumin (PV) (Hashimoto et al., 2003), or the neuropeptide, somatostatin (SST) (Morris et 
al., 2008), whereas the ~50% of GABA neurons that express calretinin (CR) appear to be 
unaffected (Woo et al., 1998; Hashimoto et al., 2003; Sakai et al., 2008).  
In a recent microarray study of GABA-related transcripts, the most robust difference in 
the DLPFC of subjects with schizophrenia was reduction in the expression of SST mRNA 
(Hashimoto et al., 2008b) which has subsequently been confirmed by real-time qPCR and in situ 
hybridization (Morris et al., 2008; Hashimoto et al., 2008b). SST is expressed in a subpopulation 
of GABA neurons that do not contain either PV or CR (Kubota et al., 1994; Gonzalez-Albo et 
al., 2001; Gonchar and Burkhalter, 2003; Sugino et al., 2006) and target distal dendritic shafts of 
pyramidal cells (Hendry et al., 1984; DeLima and Morrison, 1989; Kawaguchi and Kubota, 
1996; Melchitzky and Lewis, 2008). However, the post-synaptic receptors for SST have not been 
examined in schizophrenia. 
There are six known G-protein coupled somatostatin receptor (SSTR) subtypes (SSTR1-
5) with SSTR2 having two isoforms (SSTR2a and SSTR2b) (Moller et al., 2003). Mice with 
selective knockouts of the receptor subtypes demonstrate that the most abundant of these 
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receptors are SSTR1 and SSTR2 (Videau et al., 2003); furthermore, SSTRs have a putative 
inhibitory effect on neuronal excitability (Vezzani and Hoyer, 1999; Baraban and Tallent, 2004) 
suggesting that SSTR1 and SSTR2 are the major receptor subtypes for the modulation of 
excitability of pyramidal neurons by SST. Consistent with this hypothesis SSTR1 immuno-
labeled cells have a putative pyramidal morphology and have labeled ascending processes in the 
rat isocortex (Hervieu and Emson, 1998); similarly, SSTR2-labeled cells in the rat isocortex have 
a putative pyramidal morphology, and have labeled ascending processes (Schindler et al., 1997) 
suggesting a postsynaptic localization of these subtypes in pyramidal neurons. 
Consequently, in order to determine if the levels of SSTR1 and SSTR2 mRNAs are 
altered, we used in situ hybridization and autoradiographic analyses to quantify SSTR1 and 
SSTR2 mRNA expression in the DLPFC area 9 from 23 pairs of subjects with schizophrenia or 
schizoaffective disorder and matched normal control subjects in which we had previously 
measured SST mRNA expression using an identical approach (Morris et al., 2008). 
 
 
5.3 MATERIAL AND METHODS 
Human Subjects. With the consent of next-of-kin, brain tissue specimens were obtained from 
the Allegheny County Medical Examiner’s Office at the time of autopsy. Twenty-three subjects 
with schizophrenia (n = 15) or schizoaffective disorder (n = 8) were each matched to 1 normal 
control subject for sex, and as closely as possible for age and postmortem interval (PMI) (Table 
1). Subject groups did not differ in mean age, PMI, brain pH, RNA integrity number (RIN), or 
tissue storage time at -80° C (for all t(44) < 1.61; p > 0.11). Additional demographic and clinical 
details are provided in our previous study of SST mRNA expression in this subject cohort 
(Morris et al., 2008). An independent committee of experienced research clinicians made 
consensus DSMIV (Diagnosis and Statistical Manual of Mental Disorders (American Psychiatric 
Association, 1994)) diagnoses based on structured interviews conducted with family members of 
the deceased and a review of medical records. All procedures were approved by the University of 
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Pittsburgh’s Institutional Review Board for Biomedical Research and Committee for Oversight 
of Research Involving the Dead. 
 
Tissue preparation. For each brain specimen, coronal blocks from the right frontal cortex were 
immediately frozen and stored at -80°C. Serial sections (20 μm) containing the superior frontal 
gyrus were cut on a cryostat, thaw-mounted onto glass slides and stored at -80°C until processed. 
Adjacent sections were collected into tubes containing Trizol (Invitrogen Corp, Carlsbad, CA) in 
order to obtain RNA for RIN measures using the Agilent Bioanalyzer 2100 (Agilent 
Technologies, Inc., Santa Clara, CA) according to the manufacturer’s protocol as previously 
described (Hashimoto et al., 2008a). The location of DLPFC area 9 was identified by 
cytoarchitectonic criteria in Nissl-stained sections as previously described (Glantz et al., 2000; 
Volk et al., 2000; Volk et al., 2001). Three sections per subject for each transcript, at intervals of 
approximately 300 µm, were matched for anterior-posterior location within subject pairs, and 
used to assess SSTR1 and SSTR2 mRNA expression. 
 
In situ hybridization. Templates for the synthesis of the antisense and sense riboprobes for 
human SSTR1 and SSTR2 mRNAs were first generated by polymerase chain reaction (PCR). 
The specific primers amplified 465 and 247 base pair fragments of human SSTR1 and SSTR2, 
respectively. These fragments corresponded to bases 886-1370 of the human SSTR1 (GenBank 
NM_001049) and 1018-1264 of the human SSTR2 (GenBank NM_001050) genes. Nucleotide 
sequencing confirmed 100% homology of the amplified fragment to the previously reported 
sequences. The fragments were then subcloned into a plasmid (pSTBlue-1, Novagen, Madison, 
WI). The antisense and sense riboprobes were transcribed in the presence of 
35
S-CTP 
(Amersham Biosciences, Piscataway, NJ) using T7 and SP6 RNA polymerase, respectively. 
DNase I was used to digest the DNA template. The riboprobes were purified using RNeasy mini 
spin columns (Qiagen, Valencia, CA). 
For each matched subject pair, one section from each pair was processed side-by-side in three 
separate runs for each gene of interest. Prior to the hybridization reaction, tissue sections were 
fixed with 4% paraformaldehyde in PBS solution, acetylated with 0.25% acetic anhydrate in 0.1 
M triethanolamine/0.9% NaCl for 10 minutes, dehydrated with a graded alcohol series, and then 
defatted in chloroform for 10 minutes. The sections were then hybridized with 
35
S-labeled 
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riboprobes (1.0 X 10
6
 cpm/μl) in hybridization buffer at 56°C for 16 hours. The hybridization 
buffer contained 50% formamide, 0.75 M NaCl, 20 mM 1,4-piperazine diethane sulfonic acid, 
pH 6.8, 10 mM EDTA, 10% dextran sulfate, 5X Denhardt’s solution (0.2 mg/ml Ficoll, 0.2 
mg/ml polyvinylpyrrolidone, 0.2 mg/ml BSA), 50 mM dithiothreitol, 0.2% SDS, and 100 μg/ml 
yeast tRNA. Following the hybridization reaction, sections were washed in a solution of 0.3 M 
NaCl, 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, and 50% formamide at 63°C, treated with 
RNase A (20 μg/ml) at 37°C, washed in 0.1 X SSC (1.5 mM NaCl, 150 μM sodium citrate) at 
67°C, dehydrated through a graded ethanol series, and air dried. Sections from both subjects in a 
pair were exposed on the same BioMax MR film (Kodak, Rochester, NY) for 7 days, and then 
coated with undiluted NTB2 emulsion (Kodak) for SSTR2 and NTB2 emulsion diluted 2:1 with 
water for SSTR1. Utilizing DLPFC sections from control subjects, different emulsion exposure 
times were systematically evaluated in order to achieve an optimal signal to noise ratio. The 
emulsion was exposed for 77 and 71 days at a constant temperature of 4°C for SSTR1 and 
SSTR2, respectively. The slides were developed with D-19 (Kodak) and counterstained with 
Cresyl-violet. 
 
Quantification of mRNA expression levels. Each section was randomly coded, so that subject 
number and diagnosis were unknown to the single rater (HMM). Autoradiographic films were 
trans-illuminated and captured on video camera under controlled conditions, digitized, and 
analyzed with a Microcomputer Imaging Device (MCID; Imaging Research Inc., London, 
Ontario, Canada). Digitized images of adjacent sections stained with cresyl violet were 
superimposed onto autoradiographic images to draw contours of the full cortical thickness of the 
zones of area 9 that were cut perpendicular to the pial surface. Optical density (OD) measures 
within each sampled area were calibrated to radioactive carbon-14 standards (ARC Inc., St. 
Louis, MO), exposed on the same autoradiographic film, and expressed as nanocuries per gram 
(nCi/g) of tissue. The mean (SD) total area of gray matter sampled in control subjects and 
subjects with schizophrenia was 360 (178) and 344 (117) mm
2
 for the SSTR1 riboprobe, 
respectively, and 358 (185) mm
2
 and 304 (91) mm
2
 for the SSTR2 riboprobe, respectively.  
SSTR2 mRNA expression as a function of cortical layer was determined in a series of cortical 
traverses (1-2 mm in width) extending from the pial surface to the white matter. Three cortical 
traverses were sampled for each section (nine traverses per subject). Each traverse was divided 
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into 50 equal bins parallel to the pial surface and the optical density was determined for each bin. 
These bins were then combined into zones that approximated laminar boundaries based on 
previous studies (Akbarian et al., 1995; Pierri et al., 1999). These zones (i.e., bins 1-5, 6-15, 16-
25, 26-30, 31-40, and 41-50) corresponded to layers 1, 2/superficial 3 (2/3s), deep 3 (3d), 4, 5, 
and 6, respectively (Figure 20). The mean OD was calculated for each zone. Background 
measures were sampled from deep white matter where no specific expression of SSTR 2 mRNA 
was observed. All sampled areas were corrected by subtracting the corresponding background 
measure from the same slide.  
 
Typical and Atypical Antipsychotic-exposed Monkey Triads. As described previously (Dorph-
Petersen et al., 2005), experimentally naive, male macaque monkeys (Macaca fasicularis), 4.5 – 
5.3 years of age, were chronically exposed to twice daily oral doses of haloperidol, olanzapine or 
placebo (n = 6 monkeys per group) for 17–27 months. The doses of haloperidol and olanzapine 
were gradually increased until the monkeys were receiving 24–28 mg of haloperidol or 11.0 – 
13.2 mg of olanzapine per day. The final trough drug plasma levels were within the range 
associated with clinical efficacy in humans (~1.5 ng/ml for haloperidol and ~15 ng/ml for 
olanzapine) (Dorph-Petersen et al., 2005). Matched by terminal body weight, monkeys were 
euthanized in triads (one animal from each group) on the same day. Brains were rapidly 
removed, and the right frontal lobe was cut into coronal blocks, frozen in isopentane on dry ice 
and stored at –80°C. Serial coronal sections (16 mm) were cut from the slabs containing the 
anterior one-third of the principal sulcus and mounted on glass slides. The antisense and sense 
riboprobes were transcribed in the presence of 
35
S-CTP (PerkinElmer, Waltham, MA, USA) 
using T7 and SP6 RNA polymerase, respectively. Two sections evenly spaced at 224 mm were 
hybridized with an antisense RNA probe against human SSTR2 mRNA as described above in the 
human study. The optical density for SSTR2 mRNA was measured in the gray matter of the 
DLPFC bordered by the cingulate and principal sulci and corrected by subtracting the white 
matter density measures. Density values of two sections were averaged before statistical analysis. 
In addition, since SSTR2 mRNA is expressed at relatively lower levels in the human DLPFC and 
monkey PFC, 
33
P-CTP (PerkinElmer, Waltham, MA, USA), a relatively stronger emitter, was 
used for radiolabeling in a separate experiment in order to increase detectability and confirm the 
results from the 
35
S-labeled riboprobe. Two sections evenly spaced at 224 mm were hybridized 
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with the antisense RNA probe against human SSTR2 mRNA as described above. Optical density 
was measured and averaged for statistical analyses as described above.  All studies were carried 
out in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were 
approved by the University of Pittsburgh Institutional Animal Care and Use Committee. 
   
Haloperidol-Exposed Monkeys. In order to confirm our results from the monkey triad 
experiment and to mimic the treatment of schizophrenia with high doses of haloperidol, 4 pairs 
of young adult, male macaque monkeys (Macaca fascicularis), matched for age and weight, were 
chronically exposed to haloperidol decanoate (mean [±SD] trough plasma level, 4.3 ± 1.1 
ng/mL) and benztropine mesylate (1 mg b.i.d.) to treat extrapyramidal symptoms for 9-12 
months, as previously described (Pierri et al., 1999). Processing of monkey brain tissue was 
conducted as previously described (Hashimoto et al., 2003). Briefly, coronal sections with a 
thickness of 16 µm were cut from fresh-frozen tissue blocks containing the middle one-third of 
the principal sulcus. Three pairs of serial sections spaced ~160 µm apart from each other for each 
monkey (6 sections/monkey) were processed for SSTR2 mRNA expression utilizing the 
35
S-
labeled riboprobe as described above. The optical density was measured and averaged for 
statistical analyses as described in the above monkey study.  All sampled areas were corrected by 
subtracting corresponding background measures from the same section. 
 
Statistical analyses. Analyses were performed on SPSS (SPSS Inc., Chicago, IL). Analysis of 
covariance (ANCOVA) models were used to test differences in SSTR1 and SSTR2 mRNA 
expression between control subjects and subjects with schizophrenia. The data were averaged 
across the three sections for each subject before statistical analysis. The first ANCOVA model 
used diagnostic group as the main effect, pair as a blocking effect, and storage time and RIN as 
covariates. The pair effect reflects the matching of individual subject pairs for sex, age, and PMI. 
RIN was included as a covariate because it reflects mRNA integrity (Stan et al., 2006). Subject 
pairing may be considered an attempt to balance the two diagnostic groups with regard to the 
experimental factors instead of a true statistical paired design. Thus, to validate the first model, a 
second ANCOVA model was performed with a main effect of diagnostic group and covariates of 
sex, age, PMI, RIN, and storage time. Storage time as a covariate was not significant in either 
model and, thus was excluded in the reported analyses. Both models produced comparable 
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results for diagnostic group effect; however, because the effect of age on SSTR1 and SSTR2 
mRNA expression was significant, the results of the second model are reported.  
For the laminar analysis, multiple comparisons were controlled by adjusting for 
simultaneous inference of significance levels using the Bonferroni-Holm method (Volk et al., 
2000) in which p values are ordered from the smallest (i=1) to the largest (i=N) among multiple 
comparisons; the significance level for each comparison is defined as α=0.05/([N+1]-i).  
The potential influence of sex, diagnosis of schizoaffective disorder, history of substance 
abuse/dependence, medications at time of death, or death by suicide on the within-pair 
percentage of differences in mRNA expression was assessed by two-sample t-test analyses. 
Correlations were assessed by Pearson’s correlation analyses. 
 For the antipsychotic-treated monkey triads, the effects of drug exposure on mRNA 
expression levels were evaluated by a one-way analysis of variance (ANOVA). Tukey’s multiple 
comparison test was used in post-hoc comparisons across treatment groups. For the haloperidol-
treated monkey pairs, paired t-test analyses were used to assess the effects of treatment group on 
SSTR2 mRNA expression. 
 
 
5.4 RESULTS 
Specificity of SSTR1 and SSTR2 Riboprobes. Several lines of evidence confirm the specificity 
of the riboprobe for SSTR1 and SSTR2 mRNAs used in this study. First, The laminar 
distribution of SSTR1 mRNA is similar to that previously reported for SSTR1 mRNA in the 
human frontal cortex (Thoss et al., 1996). Specifically, the density of SSTR1 mRNA was high in 
superficial and middle layers and intermediate in the deep layers (Figure 18A). Similarly, the 
laminar distribution of SSTR2 mRNA is similar to reports in previous studies for SSTR2 mRNA 
in the human frontal cortex and immuno-positive cell bodies in the human temporal cortex 
(Thoss et al., 1996; Schindler et al., 1997). SSTR2 mRNA expression was primarily expressed in 
the deep layers (5 and 6) (Figure 18B). Second, emulsion-coated sections demonstrated silver 
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grain clusters over large, faintly Nissl-stained neuronal nuclei, whereas the smaller and more 
intensely stained glial nuclei lacked silver grains (data not shown). Third, sense riboprobes for 
SSTR1 and SSTR2 mRNA showed an absence of signal above background (data not shown).  
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Figure 18 Representative film autoradiograms from pairs of control subjects (A, B) and matched 
subjects with schizophrenia (A’, B’).  
The densities of hybridization signals are represented in a pseudocolor manner according to the 
calibration bar (right side; applies to both panels in a row). The solid and dashed lines indicate 
the pial surface and the gray/white matter border, respectively. The white bar (in B) represents 1 
mm and applies to all panels. Expression of SSTR1 mRNA is not significantly altered in the 
subject with schizophrenia (A’) as compared to the control subject (A). Expression of SSTR2 
mRNA is reduced in the deep layers of the subject with schizophrenia (B’) as compared to the 
control subject (B). 
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Expression of SSTR1 and SSTR2 in DLPFC Area 9. We previously reported reduced SST 
mRNA expression by microarray, qPCR, and in situ hybridization in the DLPFC of subjects with 
schizophrenia (Hashimoto et al., 2008a). This change in SST mRNA expression could affect the 
expression of postsynaptic receptors; therefore, we assessed the expression levels of the 
transcripts that encode for the highest expressing SST receptors (Videau et al., 2003), SSTR1 
and SSTR2, in the DLPFC area 9 of subjects with schizophrenia and matched control subjects. 
Quantitative measures of SSTR1 mRNA expression revealed that the mean (±SD) optical density 
of gray matter was not significantly (F(1,39) = 2.85; p = 0.10) altered in subjects with 
schizophrenia (45.4 ± 9.2 nCi/g) compared to control subjects (49.6 ± 8.9 nCi/g) (Figure 19A). 
In contrast, quantitative measures of SSTR2 mRNA expression revealed a significant reduction 
(F(1,39) = 5.32; p = 0.03) of 19.1% in mean (±SD) OD in subjects with schizophrenia (19.0 ± 6.4 
nCi/g) as compared to control subjects (23.5 ± 6.4 nCi/g) (Figure 19B). 
Qualitative impressions of SSTR2 mRNA expression (Figure 18B) suggested 
predominant SSTR2 mRNA distribution in the deeper layers; therefore, we examined the OD 
measures by layer (Figure 19). Because of the high density of SST mRNA+ neurons in layers 2-
superficial 3 (2/3s) (Morris et al., 2008), these layers were combined and distinguished from 
deep layer 3 (3d). SSTR2 mRNA expression was significantly decreased by 20.4% in layer 5 and 
by 28.7% in layer 6 (F(1,39) = 7.33, p = 0.01; F(1,39) = 22.75, p < 0.0001, respectively).  
Consistent with the absence of a group difference in the expression of SSTR1 mRNA, the 
within-pair percent differences in SSTR1 mRNA expression were not significantly correlated (r 
= 0.17, p = 0.43) with those for SST mRNA in the same subjects. In contrast, within-pair 
percentage differences in SSTR2 mRNA expression were significantly correlated with those 
found for SST mRNA gray matter expression (r = 0.77, p < 0.0001). 
 
Examination of Factors that May Affect Expression of SSTR2 mRNA. In the second 
ANCOVA model, age was a significant (F(1,39) = 4.72; p < 0.036) determinant of SSTR2 mRNA 
expression. Further analyses demonstrated that OD measures were negatively correlated with age 
in control subjects (r = -0.42; p < 0.044), but was only trending in subjects with schizophrenia (r 
= -0.39; p = 0.067). However, the within-subject pair percent differences in SSTR2 mRNA 
expression did not differ as a function of sex, diagnosis of schizoaffective disorder, diagnosis of 
substance or alcohol abuse at time of death (ATOD), use of antidepressant medication ATOD, 
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Figure 19 SSTR1 and SSTR2 mRNA expression levels assessed by autoradiographic film 
optical density (OD) measures in DLPFC area 9 of subjects with schizophrenia (solid gray 
circles) and control subjects (solid black circles).  
Pairs are connected by a solid black line and the mean expression levels for each subject group 
are represented by a horizontal line. The expression of SSTR1 mRNA is not significantly altered 
(A), but expression of SSTR2 mRNA is significantly reduced (B). 
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Figure 20 Mean (SD) expression levels of SSTR2 mRNA by layer as assessed by film autoradiography 
optical density (OD) measures in each cortical layer.  
* Adjusted p < 0.05. ** Adjusted p < 0.001. 
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use of benzodiazepines/valproate ATOD, suicide, antipsychotic medication use ATOD, or use of 
haloperidol ATOD (all t(21) < 1.74, all p > 0.10) (Figure 21).  
To evaluate the potential effect of long-term exposure to typical and atypical 
antipsychotic medications, we examined the expression of SSTR2 mRNA in the PFC of 
monkeys chronically exposed to placebo, haloperidol, or olanzapine (n = 6 per group). Utilizing 
a 
35
S-labeled riboprobe, the laminar distribution of SSTR2 mRNA in the 3 groups matched the 
pattern observed in the human DLPFC (Figure 22). There was a significant effect of treatment 
group (F2,15 = 7.29; p = 0.006) on the expression of SSTR2 mRNA. Post-hoc analysis revealed a 
significant reduction in the mean (±SD) OD in the haloperidol group (26.4 ± 3.3 nCi/g) as 
compared to the placebo group (42.3 ± 9.3 nCi/g) or the olanzapine group (37.6 ± 8.2 nCi/g) (p = 
0.005 and p = 0.048, respectively); there was no significant difference (p = 0.53) between the 
placebo and olanzapine groups. In order to confirm these results, we also utilized 
33
P-CTP, a 
relatively high emitter, to radiolabel a separate SSTR2 riboprobe and repeated the experiment in 
the same monkey cohort. The 
33
P-labeled riboprobe revealed a laminar distribution of SSTR2 
mRNA that matched the pattern seen with the 
35
S-labeled riboprobe in humans and monkeys 
(Figure 22). Similar to our previous experiment, there was a significant effect (F2,15 = 5.18; p = 
0.02) of treatment group of which there was a significant reduction (p = 0.02) in the mean (±SD) 
OD in the haloperidol group (20.4 ± 5.1 nCi/g) as compared to the placebo group (31.6 ± 6.4 
nCi/g); however, the mean (±SD) OD of the olanzapine group (27.7 ± 6.8 nCi/g) was not 
significantly different than the haloperidol group (p = 0.13) or the placebo group (p = 0.54).  
These results suggested that chronic exposure to haloperidol affects the expression of SSTR2 
mRNA in the PFC which we did not observe in the subjects with schizophrenia (Figure 21); 
therefore, we wanted to confirm these results in a separate monkey cohort. Thus, we examined 
the expression of SSTR2 mRNA in the PFC of monkeys that were chronically exposed to higher 
levels of haloperidol decanoate (mean trough plasma levels >4 ng/mL) as compared to the 
haloperidol-exposed group in the previous monkey cohort (steady-state trough plasma levels of 
~1.5 ng/mL). Mean (±SD) OD did not differ (t(3) = -1.78; p = 0.17) between the haloperidol-
exposed monkeys (38.8 ± 5.7 nCi/g) and their sex-, age-, and weight-matched controls (46.8 ± 
9.0 nCi/g). 
Since SSTR2 mRNA expression was significantly affected by chronic exposure to haloperidol in 
at least one of the monkey cohorts, we wanted to further examine the effect of haloperidol or, 
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Figure 21 The effects of potential confounding factors on the expression differences in SSTR2 
mRNA in subjects with schizophrenia.  
The bars represent the mean (SD) percent differences from control subjects for SSTR2 mRNA 
within subject pairs; numbers above each bar indicate the number of subject pairs. Sex, diagnosis 
of schizoaffective disorder, diagnosis of substance or alcohol abuse or dependency ATOD, use 
of antidepressant medications ATOD, use of benzodiazepines/valproate ATOD, death by suicide, 
use of antipsychotic medication ATOD, or use of haloperidol ATOD did not significantly affect 
the expression changes in SSTR2 mRNA. 
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Figure 22 The effect of chronic exposure to antipsychotic medications on the expression of 
SSTR2 mRNA in the monkey PFC.  
Representative film autoradiograms demonstrate the expression of SSTR2 mRNA utilizing a 
35
S-
labeled riboprobe (upper panels) and a 
33
P-labeled riboprobe (lower panels) in the PFC of a 
control (left panels), a haloperidol-exposed (center panels) and an olanzapine-exposed (right 
panels) monkey. The densities of hybridization signals are presented in a pseudocolor manner 
according to the calibration bars (left; applies to all panels in a row). Solid and dashed lines 
indicate the pial surface and the gray/white matter border, respectively. Expression of SSTR2 
mRNA was assessed between the cingulate sulcus (CS) and the principal sulcus (PS). Graphs 
(right) show the mean (±SD) expression levels of SSTR2 mRNA utilizing a 
35
S-labeled 
riboprobe (upper) and 
33
P-labeled riboprobe (lower) in the placebo-, haloperidol-, and 
olanzapine-exposed monkey groups. 
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more generally, typical antipsychotic medication usage in the subjects with schizophrenia. The 
within-subject pair percent differences in SSTR2 mRNA expression did not differ as a function 
of use of haloperidol ATOD (Figure 21). Furthermore, when we removed all subject pairs in 
which the subject with schizophrenia was taking a typical antipsychotic medication ATOD and 
performed an ANCOVA on the remaining pairs (n = 11 pairs) there was a significant reduction 
(F(1,15) = 4.81; p = 0.04) of 19.9% in mean (±SD) OD in subjects with schizophrenia (20.1 ± 4.5 
nCi/g) as compared to control subjects (25.1 ± 7.1 nCi/g) 
 
5.5 DISCUSSION 
The expression level of SSTR2 mRNA was significantly decreased in deep cortical layers 5 and 
6 of the DLPFC area 9 in subjects with schizophrenia compared to matched controls; in contrast, 
SSTR1 mRNA expression did not differ between subjects groups. Furthermore, the observed 
differences in SSTR2 mRNA, but not SSTR1 mRNA, expression were significantly correlated 
with those in SST mRNA in the same subject pairs suggesting that the down regulation of 
SSTR2 is related to the alteration found in the SST interneuron population (Morris et al., 2008) 
although a cause and effect relationship cannot be clearly established. Furthermore, we found a 
significant effect of chronic haloperidol exposure on SSTR2 mRNA expression in the PFC of 
one of the monkey cohorts; however, haloperidol or typical antipsychotic usage ATOD was not 
the cause of the altered SSTR2 mRNA expression in subjects with schizophrenia. 
Several lines of evidence suggest that the SSTR2 mRNA expression deficit is not a result 
of factors frequently associated with illness. First, the within-subject pair percent differences in 
SSTR2 mRNA expression did not differ as a function of the use of antipsychotic medications 
ATOD (Figure 21). Second, SSTR2 mRNA expression was not altered in the PFC of monkeys 
with chronic long-term exposure to atypical (olanzapine) antipsychotics (Figure 22). Third, 
within-subject pair percent differences in SSTR2 mRNA expression did not differ between 
subject pairs in which the subject with schizophrenia was receiving haloperidol ATOD and pairs 
in which the subject with schizophrenia was not taking haloperidol ATOD (Figure 21). 
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Consistent with this observation, when all subject pairs in which the subject with schizophrenia 
was taking typical antipsychotics ATOD were removed from the analyses SSTR2 mRNA 
expression remained significantly reduced. Furthermore, long-term haloperidol exposure in rats 
demonstrated normal levels of SST binding in the frontal cortex after one week of withdrawal 
suggesting that previous haloperidol exposure does not permanently affect SSTR expression 
(Perez-Oso et al., 1990). Finally, neither sex, diagnosis of schizoaffective disorder, diagnosis of 
substance or alcohol abuse ATOD, use of antidepressant or benzodiazepines/valproate ATOD, 
nor death by suicide accounted for the decreased expression of SSTR2 mRNA in the subjects 
with schizophrenia. 
In the neocortex of rats, SSTR2s are primarily concentrated in the ascending dendrites of 
pyramidal neurons located in the deep layers (Schindler et al., 1997). Furthermore, in the rat and 
monkey neocortex SST-containing interneurons predominately innervate the dendritic shafts of 
pyramidal neurons (Hendry et al., 1984; DeLima and Morrison, 1989; Kawaguchi and Kubota, 
1996; Melchitzky and Lewis, 2008). Combined with our study and others (Thoss et al., 1996; 
Schindler et al., 1997) demonstrating a primary localization of SSTR2 mRNA or 
immunoreactive-cell bodies in the deep layers of the neocortex of the human, these data suggest 
that SSTR2 is primarily expressed by layer 5 and 6 pyramidal cells on their ascending dendritic 
shaft which receive input from SST-containing inhibitory interneurons.  
SSTRs have a putative inhibitory effect on neuronal excitability (Vezzani and Hoyer, 
1999; Baraban and Tallent, 2004). In the presence of SST, SSTRs hyperpolarize rodent 
hippocampal pyramidal neurons in vitro (Pittman and Siggins, 1981) by augmenting M-currents 
(Moore et al., 1988) and voltage-insensitive K
+
 leak current (Schweitzer et al., 1998). These data 
suggest that in the DLPFC of subjects with schizophrenia there is not only a reduction in 
presynaptic inhibitory drive onto pyramidal dedritic domains as evidenced by a robust reduction 
in SST mRNA expression (Morris et al., 2008), but there is also a reduction in postsynaptic 
inhibitory drive as evidenced by the reduction in SSTR2 mRNA expression. Reductions in both 
presynaptic and postsynaptic inhibitory drive suggest that the correlated changes in SST and 
SSTR2 mRNA expression are a result of an “upstream” event that effects inhibitory drive in 
pyramidal neurons. For example, a leading hypothesis concerning the pathophysiology 
underlying schizophrenia is that there is a disruption in the glutamatergic system which 
eventually leads to disruptions in other neurotransmission systems such as disturbances seen in 
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the GABA system (Lewis and Moghaddam, 2006). Several converging lines of evidence support 
this hypothesis. First, many of the putative schizophrenia susceptibility genes are associated with 
excitatory neurotransmission (Harrison and Owen, 2003; Moghaddam, 2003) suggesting that 
genetic risks involving this type of neurotransmission may be a key component in the etiology of 
schizophrenia. Second, administration of antagonists of the NMDA subtype of glutamate 
receptors impair cognitive functions in control subjects similar to those found in subjects with 
schizophrenia (Krystal et al., 1994; Adler et al., 1999; Newcomer et al., 1999; Krystal et al., 
2000). For example, control subjects receiving subanesthetic doses of ketamine demonstrated 
reductions in working memory performance and increases in thought disorder similar to those 
seen in subjects with schizophrenia (Adler et al., 1999). Third, many post-mortem studies in 
individuals with schizophrenia have demonstrated significant alterations in glutamate receptor 
efficacy and subunit transcript and protein expression (Konradi and Heckers, 2003). Therefore, 
the coordinated reduction in the expression of SST and SSTR2 mRNA could be a compensatory 
mechanism which reduces inhibitory drive in order to increase the efficacy of excitatory drive on 
the dendritic domain of pyramidal neurons in the DLPFC of subjects with schizophrenia. 
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6.0  GENERAL DISCUSSION 
Previous studies raised the possibility that the SST-containing interneurons in the DLPFC of 
indivuals with schizophrenia are altered. Therefore, in order to better understand the 
pathophysiology of SST interneurons and how they could contribute to cognitive deficits in 
schizophrenia, this thesis outlines the alterations in and possible upstream mechanisms of 
alterations in SST interneurons in the DLPFC of individuals with schizophrenia. We concluded 
that the correlated alterations in SST and GAD67 mRNAs indicate that GABA neurotransmission 
from SST interneurons is dysfunctional in schizophrenia and these changes are likely 
downstream from alterations in neurotrophin signaling via the trkB receptor. Furthermore, the 
correlated reductions in SST and SSTR2 mRNAs are indicative of reduced inhibitory modulation 
at the dendritic domain of pyramidal neurons. We interpret these correlated changes to represent, 
in schizophrenia, a downstream compensatory response to reduced excitatory drive at the 
dendritic domain of pyramidal cells in order to increase the efficacy of excitatory inputs to 
pyramidal cells in the DLPFC of subjects with schizophrenia.  
Since SST interneurons seem to play a critical role in the coordinated firing of pyramidal 
cells during working memory function, these results indicate that alterations in SST-containing 
interneurons in the DLPFC of subjects with schizophrenia represent a plausible 
neuropathological entity that contributes to altered theta oscillations and, therefore, to the 
manifestation of the clinical manifestation of altered working memory performance. In addition, 
previous postmortem studies have suggested that in the DLPFC of subjects with schizophrenia 
parvalbumin-containing interneurons such as the chandelier class of GABA neurons have 
reduced GABA synthesis (Lewis et al., 2005) and lead to altered coordination of pyramidal cell 
firing in the gamma range. As will be explained later in this discussion, synchrony of pyramidal 
cell firing at the gamma range is also important for working memory function; therefore, these 
data combined with the data from this dissertation suggest that the coordinated network activity 
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necessary for normal working memory function is severely altered in individuals with 
schizophrenia. 
In the following sections, I will integrate the data from this dissertation into the existing 
literature to propose a working model of schizophrenia that outlines the disease process leading 
to working memory dysfunction, discuss some limitations of the studies in the thesis, and 
propose future directions. 
 
6.1 PROPOSED DISEASE PROCESS OF SCHIZOPHRENIA 
It is paramount that the results from the human postmortem studies from this dissertation be 
integrated into a plausible disease process that can explain the etiology that leads to the observed 
alterations in the neural substrate, where the observed alterations fall within a cascade of events 
(i.e. Is it a causal factor, a downstream consequence, or a compensatory response?), and how the 
observed alterations in the neural substrate lead to the neuropathophysiology that underlies the 
clinical symptoms. Such a disease model is important for the development of novel treatments 
because it would allow for the identification of alterations that are most proximal to the 
neuropathophysiology (i.e. altered network activity) underlying a core feature of the disease (i.e. 
working memory dysfunction).  
 Chapter 1.2.2 outlined previous studies demonstrating selective reductions of GAD67 
mRNA in PV-containing interneurons representing an alteration in the neural substrate of the 
DLPFC of subjects with schizophrenia. This dissertation demonstrated alterations in mRNAs 
involved in the functionality of SST-containing interneurons which represent a novel 
neuropathological entity in the DLPFC of subjects with schizophrenia and a plausible upstream 
mechanism involving alterations in trkB signaling. The following sections will propose a model 
of the disease process incorporating the observations of alterations in PV-containing chandelier 
and SST-containing neurons which converge on a common neuropathophysiology underlying a 
core feature of schizophrenia (Figure 23). 
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Figure 23 Proposed disease model illustrating potential cascade of events of the disease process 
in schizophrenia.  
A set of genetic liabilities and environmental risk factors produce reduced GABA signaling from 
two distinct subclasses of GABA neurons. Despite apparent compensatory responses, several 
downsteam mechanisms from alterations in these two neuron types converge to produce altered 
network activity, which gives rise to impairments in working memory. 
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6.1.1 Etiological mechanism of reduced GAD67 
This section will review an upstream causal mechanism that can account for the observed 
alteraltions seen in PV- and SST-containing neurons. This plausible mechanism was chosen 
because it can account for the data presented in this dissersation; however, many other 
possibilities exist. 
6.1.1.1 Alterations in excitatory neurotransmission in schizophrenia 
As mentioned in Chapter 5, several lines of evidence suggest that disruptions in the 
glutamatergic system in subjects with schizophrenia are a pathophysiology. Besides, the 
mentioned studies other factors that affect the efficacy or function of modulatory sites on the 
NMDA receptor or proteins involved in the NMDA downstream intracellular pathways have 
been implicated in schizophrenia. For example, variants in the gene for neuregulin 1 (NRG1) 
have been shown to increase risk for schizophrenia (Stefansson et al., 2002) and alterations in 
this protein can reduce NMDA receptor activation through interactions with its erbB4 receptors 
in the DLPFC of subjects with schizophrenia (Hahn et al., 2006). Thus, these data suggest that 
NDMA hypofunction perhaps through occurrence of variants in NRG1 could contribute to the 
neuropathophysiology of schizophrenia (Figure 23). 
Reduced excitatory transmission can be an independent neuropathology in schizophrenia 
that underlies cognitive impairments in the illness (Moghaddam, 2003). However, because 
GABA interneuronal activity is affected by glutamatergic inputs, these disturbances in excitatory 
neurotransmission found in schizophrenia could be affecting GABA neurotransmission and, thus, 
indirectly affecting working memory function. For example, blockade of NMDA glutamate 
receptors induces a robust deficit in GAD67 levels in many areas of the forebrain (Qin et al., 
1994; Bacci et al., 2002; Paulson et al., 2003). Furthermore, GABA neurons are more sensitive 
to the antagonistic effects of drugs blocking NMDA receptors, as compared to surrounding 
pyramidal neurons (Li et al., 2002) leading others to suggest that NMDA antagonists that 
reproduce cognitive deficits seen in schizophrenia primarily affect GABA neurons (Coyle, 
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2004). Therefore, these data suggest that NMDA hypofunction may be an upstream causal factor 
contributing to the reductions of GAD67 mRNA expression observed in schizophrenia (Figure 
23). 
Several lines of evidence suggest that excitatory neurotransmission may prefentially 
affect certain subtypes of interneurons, thus, explaining the selective alterations seen in PV-, but 
not CR-containing neurons in the DLFPC of subjects with schizophrenia (Chapter 1.2.2). First, 
glutamatergic drive is stronger to PV-containing than to CR-containing neurons as seen by a 
much larger total number of excitatory synapses onto PV-containing neurons than on to CR-
containing neurons in the rodent hippocampus and monkey DLPFC (Gulyas et al., 1999; 
Melchitzky and Lewis, 2003). Second, PV- and CR-containing neurons preferentially express 
different NMDA receptor subunits. In the primate cortex, approximately 50-90% of PV-
containing, but only 10% of CR-containing neurons were immunoreactive for the NR1 subunit of 
the NMDA receptor (Huntley et al., 1994; Huntley et al., 1997). Third, PV-containing 
interneurons seem to be particularly sensitive to the effects of NMDA receptor antagonists as 
demonstrated by long-term phencyclidine (PCP) exposure in the rodent. The effects of chronic 
PCP exposure were a reduction in the expression level of PV mRNA per neuron by 25% without 
any change in the density of PV mRNA-positive neurons in the rat frontal cortex (Cochran et al., 
2003). This pattern of change mimics the alterations seen in PV mRNA expression in the DLPFC 
of subjects with schizophrenia (Hashimoto et al., 2003). Together, these findings suggest that the 
selective reduction of GAD67 mRNA expression in the PV-containing neurons could be 
downstream of consequence of NMDA hypofunction (Figure 23). 
It is unclear whether alterations in SST-containing neurons are a direct consequence of 
NMDA hypofunction. However, at least one study suggests that SST-containing neurons are 
sensitive to reductions in excitatory neurotransmission. In rat somatosensory cortex, both PV- 
and SST-containing interneurons were robustly and persistently activated by thalamocortical 
stimulation in vitro (Tan et al., 2008) demonstrating SST-containing interneurons also have 
extensive excitatory inputs. This study suggests that the alterations in GAD67 and SST mRNA 
expression in the DLPFC of subjects with schizophrenia could be another downstream 
consequence of reduced excitatory drive.  
In this dissertation, we demonstrated correlated reductions in SST and its receptor, 
SSTR2, mRNA. This correlated reduction would have the effect of reducing inhibitory drive at 
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the dendritic domain of pyramidal cells. We speculated that such a reduction could be a 
compensatory mechanism in order to help increase excitatory input to the pyramidal neurons 
(Figure 23). Unfortunately, the effects of reduced exctitatory drive on the expression of SSTR2 
mRNA have not been investigated. 
Together, these data suggest that in schizophrenia there are reductions in excitatory drive 
perhaps through NMDA hypofunction mediated by alterations in NRG1 signalling. This 
reduction in excitatory drive could be an upstream causal factor of reductions in GAD67 
specifically in PV- and perhaps SST-containing neurons although a direct causal mechanism is 
unclear for SST-containing neurons. Furthermore, this reduction in excitatory drive may also 
drive compensatory reductions in SSTR2 mRNA in order to increase the efficacy of excitatory 
drive at the dendritic domain of pyramidal cells (Figure 23). 
6.1.1.2 Altered neurotrophin signaling via trkB receptors in schizophrenia  
Another possible upstream causal mechanism that could account for the reductions in 
GABA-related markers is reduced signaling through the trkB receptor. As previously mentioned 
in 1.2.2, 1.3.5, and demonstrated in this thesis, it seems that the alterations in GABA-related 
markers are specific to the SST subpopulations of GABA neurons, but not the CR interneuron 
subpopulation. Furthermore, the PV-containing neurons may also be selectively affected by 
reductions in trkB signaling. Therefore, the reductions in BDNF and trkB mRNA expression 
seen the DLPFC of subjects with schizophrenia (chapter 1.3.5) expression could be an upstream 
mechanism responsible for reductions in the affected interneuron subpopulations in 
schizophrenia. 
In the cortex, pyramidal neurons synthesize and secrete BDNF in an activity-dependent 
manner; and, BDNF acts as a growth factor for many GABA neurons that express trkB 
(Cellerino et al., 1996; Marty et al., 1997). Furthermore, activity in pyramidal neurons enhances 
dendritic growth and branching in nearby inhibitory interneurons through a BDNF-dependent 
mechanism (Jin et al., 2003) and BDNF/trkB signaling could mediate levels of GABA 
throughout the cortex (Rutherford et al., 1997). These alterations could be selective for PV and 
SST interneurons because most PV interneurons (Cellerino et al., 1996; Gorba and Wahle, 1999) 
and ~50% of SST interneurons express trkB (Gorba and Wahle, 1999), but CR interneurons do 
not (Gorba and Wahle, 1999). Furthermore, trkB hypomorphic mice demonstrate selective 
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reductions in PV mRNA and SST mRNA, but not CR mRNA expression (Hashimoto et al., 
2005). Therefore, the reduction in excitatory inputs could lead to the reductions in BDNF and 
trkB expression found in the DLPFC of subjects with schizophrenia and indirectly alter GAD67 
expression in and function of PV interneurons and at least a subset of SST interneurons (Figure 
23). 
6.1.2 Alterations in network activity of the DLPFC of subjects with schizophrenia 
converge upon a common pathophysiology 
Figure 23 summarizes the proposed disease process in which various upstream causal 
mechanisms such as NMDA hypofunction and BDNF/trkB signaling alterations can converge 
downstream to account for the alterations seen in GAD67 mRNA in PV- and SST-containing 
neurons. The reduction seen in SSTR2 mRNA was interpreted to be a compensatory mechanism 
utilized to increase excitatory drive at the dendritic domain of pyramidal neurons. However, such 
a compensatory mechanism may not be adequate to alleviate a core feature of schizophrenia, 
working memory deficits. The following sections will propose that alterations in PV- and SST-
containing neurons result in several downstream consequences resulting in alterations to 
coordinated network activity needed for the normal function of working memory is altered in the 
DLPFC of subjects with schizophrenia and can not be compensated for by a simple increase in 
efficacy in excitatory drive at the dendritic domain of pyramidal cells.  
In chapter 2 we hypothesized that alterations in SST-containing neurons affect disynaptic 
inhibition which is involved in filtering distracting stimuli and, thus, may be involved in the 
correlated reductions in sensory gating and working memory performance (Figure 23). We also 
hypothesized that the alterations in SST-containing neurons affect frontal theta EEG oscillations 
and, therefore, are involved in working memory dysfunction (Figure 23). Thus, the observed 
reductions in SSTR2 mRNA may be a compensatory response to reductions in excitatory drive; 
however, the reduction in inhibitory tone may also have deleterious effects on the coordinated 
network activity needed for working memory function. 
Furthermore, other downstream consequences from reductions in SST mRNA expression 
could be affecting the proper function of network activity. For example, somatostatin has been 
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implicated in the proper function of neurovascular coupling. Neurovascular coupling refers to the 
tightly controlled system of alterations in local blood perfusion to neurons with altered activity. 
Therefore, this coupling is thought to supply blood to cortical areas which have higher metabolic 
demands and is the basis of the signals utilized in many functional neuroimaging techniques 
(Logothetis et al., 2001). In the cerebral cortex, local GABA neurons have been implicated as the 
mediator between changes in the local activation of neurons and subsequent changes in local 
vasculature needed for changes in blood perfusion. (Kawaguchi and Kubota, 1997). This is 
supported by a study demonstrating that GABA neurons provide rich innervation onto local 
microvessels (small blood vessels within the brain) (Vaucher et al., 2000). Several lines of 
evidence suggest that SST-containing interneurons are at least one cell type involved in 
neurovascular coupling. First, evoked cell firing of single SST-containing interneurons in acute 
frontoparietal rat sections elicited contractions in neighboring microvessels (Cauli et al., 2004). 
Second, direct perfusion of somatostatin to these acute slices produced constrictions in 
microvessels (Cauli et al., 2004). Third, RT-PCR analyses demonstrated that smooth muscle 
cells from these microvessels expressed mRNAs that encode for several SSTR subtypes 
including SSTR2 mRNA (Cauli et al., 2004). Fourth, in vivo activation of SST-containing 
neurons (indicated by c-Fos-immunoreactivity) with monitoring of cerebral blood flow in rat 
frontal cortex indicates that these neurons are involved in neurovascular coupling in an intact 
system (Kocharyan et al., 2008). Furthermore, humans with small-vessel disease, or cerebral 
microangiopathy (CMA), display degeneration of the cerebral microcirculation (Roman et al., 
2002) which seems to affect the cerebral blood flow primarily in the frontal lobes (Hund-
Georgiadis et al., 2002) and is accompanied by cognitive dysfunction including reductions in 
memory task performance (Prins et al., 2005). Since occlusion of blood flow in rats has been 
shown to reduce neuronal cell firing at least in the brain stem (Sakata et al., 2000), together these 
data suggest that reduction in somatostatin expression in the DLPFC of subjects with 
schizophrenia is affecting neurovascular coupling which in turn has deleterious effects on 
neuronal cell firing and leads to dysfunction of memory tasks. Thus, although SSTR2 mRNA 
reductions may be a mechanism in which to increase excitatory drive to pyramidal cells it also 
may have deleterious affects on neurovascular coupling providing a separate mechanism in 
which to reduce working memory performance in schizophrenia (Figure 23). 
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Finally, as mentioned in chapter 6.1.2 the PV-contining subclass of GABA-containing 
interneurons are affected in the DLPFC of subjects with schizophrenia. In contrast to SST-
containing neurons, PV-containing neurons tend to innervate the perisomatic region of pyramidal 
cell suggesting that these neurons are involved in regulating the output of pyramidal cells (Lewis 
et al., 2005). Networks of chemically and electrically-coupled PV-containing neurons are 
essential for the synchronization of large cell ensembles of neurons and give rise to oscillatory 
activity in the gamma-band range (20-80 Hz) (Whittington and Traub, 2003). In the human 
DLPFC, gamma oscillations appear at the onset of, and are maintained during, the delay period 
of working memory tasks (Tallon-Baudry et al., 1998) and the power of gamma band oscillations 
increases in proportion to working memory load (Howard et al., 2003). In individuals with 
schizophrenia, deficits in working memory are associated with reductions in DLPFC gamma-
band oscillations (Cho et al., 2006). Therefore, the alterations seen in PV-containing neurons 
may impair inhibition at the perisomatic domain of pyramidal cells and consequently, contribute 
to reduced gamma-band oscillations associated with working memory dysfunction in individuals 
withs schizophrenia (Figure 23).  
These data suggest that within the DLPFC of individuals with schizophrenia there are 
selective alterations in PV- and SST-containing interneurons. Through several downstream 
mechanisms these alterations can affect neuronal network activation which ultimately contribute 
to the working memory dysfunction in schizophrenia. These mechanisms have been attributed to 
the DLPFC; however, other studies have demonstrated alterations in PV- and SST-containing 
interneurons in other brain regions of subjects with schizopohrenia (Hashimoto et al., 2008d) 
suggesting that these mechanisms are not specific to this brain region and may affect other types 
of cognitive dysfunction in subjects with schizophrenia.  
6.1.3 Diagnostic specificity of the profile of GABA-related alterations: implications for 
the etiology of schziohrenia 
Since Kraepelin, a dichotomy between schizophrenia (dementia praecox) and BPD (manic-
depressive insanity) has been classically viewed, with specific diagnostic criteria defining 
schizophrenia and BPD as separate diseases (Kempf et al., 2005). However, based on genetic and 
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neurochemical findings, many researchers are challenging this position suggesting that instead 
these disorders are different manifestations of the same disease along a “continuum” of symptom 
severity (Moller, 2003). As mentioned in 1.2.3, BPD, but not MDD, shares many susceptibility 
genes and GABA-related pathophysiology with schizophrenia. However, in chapter 3, when we 
examined the expression profile GABA-related mRNA in the DLPFC of subjects with BPD or 
MDD, to that seen in schizophrenia each disorder demonstrated unique profiles of alterations. As 
seen in Table 5, subjects with schizophrenia demonstrated selective reduction in GAD67, PV, and 
SST whereas subjects with BPD or MDD had selective reductions in PV or SST, respectively. 
No one transcript demonstrated reductions in all three disorders, suggesting that the the profile of 
alterations found in each disorder is unique and not due to some common environmental factor 
that is associated with a chronic debilitating psychiatric illness (e.g. hospitalizations or social 
isolation).  
 Instead, these unique profiles suggest each disorder has separate etiological factors 
contributing to the neuropathophysiology of the DLPFC within these individuals. Although the 
following conclusions must be confirmed by exprimentation, the selective alterations in certain 
subpopulations of GABA neurons in BPD (PV interneurons), MDD (SST interneurons), and 
schizophrenia (both PV and SST interneurons) suggests that each disorder has specific etiologies 
that uniquely affect these specific subpopulations. These could include, but are not limited to, 
alterations to the instrinsic efferents to or targets of these subpopulations of GABA neurons. 
Alternatively, place of origin of PV and SST interneurons, could be selectively affected during 
development in each of these disorders. Culture experiments and experiments involving the 
homotopic transplant of progenitors demonstrated that CR-containing interneurons originate 
from the dorsal region of the caudal ganglionic eminence (CGE) whereas PV- and SST-
containing interneurons origate from the medial ganglionic eminence (MGE) in the mouse (Xu et 
al., 2004; Butt et al., 2005). Furthermore, within the MGE of the mouse, SST interneurons 
originate from the dorsal region and PV interneurons from the caudal region (Wonders et al., 
2008). These data suggest in individuals in schizophrenia the trajectory of interneuron 
development is affected in the MGE, but not the CGE; futhermore, in individuals with BPD or 
MDD the developmental trajectories of interneurons from the dorsal or caudal regions, 
respectively, are altered. The etiologic mechanisms that would confer risk for selective 
alterations in the respective interneuron developmental trajectories remains unknown; however, 
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each of these interneuron subpopulations at least in the mouse express specific transcription 
factors important for normal development and differentiation (Butt et al., 2007) which could be 
differentially affected within these disorders.  
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Table 5 Profiles of GABA-related mRNA alterations 
Psychiatric 
Group 
Calretinin GAD65 GAD67 Parvalbumin Somatostatin 
Schizophrenia ↔    ↓(?) ↓ ↓ ↓ 
BPD ↔ ↔ ↔    ↓(?) ↓ 
MDD ↔ ↔ ↔ ↔ ↓ 
112 
 
6.2 LIMITATIONS AND FUTURE DIRECTIONS 
The studies within this thesis only examined mRNA expression of GABA-related markers. The 
functional implications of reductions in mRNA expression can only be true if there is a 
concurrent reduction in the cognate protein. Unfortunately, small peptides in the brain such as 
SST are rapidly degraded post-mortem making accurate quatification of the SST protein difficult 
(Hayes et al., 1991). However, both in the rat and monkey brain SST mRNA and protein are 
highly correlated (Hayashi et al., 1997; Vela et al., 2003) suggesting the reductions that we 
observed in SST mRNA expression reflects a concurrent reduction in the cognate protein. The 
correlation between SSTR2 mRNA and its protein is unknown, thus, confirmation of reductions 
in the protein concurrent with the reduction in mRNA must be confirmed. 
6.2.1 Confirmation that alterations in GABA neurotransmission from SST interneurons 
affect working memory 
We have argued that the correlated reductions in SST and GAD67 mRNAs in the same subjects 
suggest that GABA neurotransmission is altered in SST interneurons. However, these 
correlations are not direct evidence for a reduction in GABA neurotransmission in this 
subpopulation.  
6.2.1.1 Identification of unique markers for SST interneurons 
We did not pursue a dual-label experiment utilizing SST and GAD67 mRNAs in order to 
determine if SST interneurons express less GAD67 in schizophrenia because of a potential 
confound that we identified in Chapter 2. In the DLPFC of subjects with schizophrenia, the 
density of SST mRNA+ interneurons was significantly reduced. Because in the DLPFC of 
subjects with schizophrenia there is no reduction in neuronal density, we interpreted this finding 
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to mean that there is a normal density of SST interneurons in the DLPFC of subjects with 
schizophrenia; however, some of these interneurons do not express detectable levels of SST 
mRNA. This suggests that any co-labeling study that is performed with SST mRNA in 
schizophrenia would be inaccurate since the marker (SST mRNA) is not detectable in some 
neurons. Therefore, we propose a microarray study in which SST interneurons are selectively 
isolated via laser microdissection in order to determine potential alternative markers for SST 
interneurons that are not altered in schizophrenia. 
6.2.1.2 Proof of principle experiment: Selective reductions in GABA neurotransmission in 
SST interneurons 
In Chapter 2 and in 2.1.2, we predicted that the functional consequences of alterations in SST 
interneurons would include reductions in disynaptic inhibition and theta oscillations leading to 
working memory deficits. Therefore, we propose a series of experiments utilizing mouse models 
in which SST interneurons express reduced levels of GABA in order to determine if our 
predictions have merit. These could include either mice with genetic manipulations in which 
GAD67 is selective knocked out or in vivo knock-down of GAD67 in SST interneurons utilizing 
viral-mediated RNA-interference. 
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7.0  CONCLUSION 
In the DLPFC of individuals with schizophrenia, GAD67 mRNA levels were reduced in layers 2-
5 with reduced PV mRNA expression in layers 3 and 4 which suggested that another 
subpopulation of GABA neurons were affected in layers 2 and 5. The high density of SST 
interneurons in prefrontal laminar layers 2/superficial 3 and 5 suggested that this subpopulation 
of GABA neurons were the affected neurons; consistent with this line of reasoning, of several 
GABA-related mRNA expression alterations, reductions in the level of SST mRNA were the 
most robust in the DLFPC of subjects with schizophrenia. This thesis confirmed and elucidated 
the alterations in the SST-containing subpopulation of the DLPFC of individuals with 
schizophrenia.  
In Chapter 2, we demonstrated selective reductions in the expression of SST mRNA in 
layers 2-superificial 6 and that the changes in SST mRNA expression correlated with GAD67  
mRNA expression changes in the same subject pairs. Furthermore, this reduction is likely 
mediated by impaired neurotrophin signaling through the trkB receptor. In Chapter 3, we 
illustrated that the profile of GABA-related mRNA expression changes were specific to 
schizophrenia suggesting that other major psychiatric disorders have differing etiologic factors 
contributing to their respective disease processes. Chapter 4 demonstrated that the affected SST 
neurons do not include the subset that colocalizes NPY. And, finally, Chapter 5 illustrated that 
the reductions in SST mRNA expression parallels reductions the expression of mRNA encoding 
for its post-synaptic receptor, SSTR2.  
We concluded that the correlated changes in SST and GAD67 mRNAs represent 
alterations in GABA neurotransmission from the subpopulation of SST-, but not NPY-, 
containing interneurons; furthermore, the correlated changes in SST and SSTR2 mRNAs reflect 
a dysfunction of inhibition at the dendritic domain of pyramidal neurons. We interpret these 
findings to indicate that, in the DLFPC of inviduals with schizophrenia, the pre- and post-
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synaptic reductions in inhibition from SST interneurons is an attempt to compensate for a general 
reduction of excitatory inputs to the dendritic domain of pyramidal neurons. In addition, because 
SST-containing interneurons play a role in disynaptic inhibition and the synchronization of 
pyramidal neuron firing in the theta range, both of which are likely important for working 
memory, alterations in this subpopulation of GABA neurons contribute to the cognitive 
dysfunction in schizophrenia. 
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